



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 31/18, 31/47, 31/155, 31/655, C07C 247/16, 251/38, 279/18, 311/64, C07D 453/02</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/27591</p> <p>(43) International Publication Date: 8 December 1994 (08.12.94)</p>
<p>(21) International Application Number: PCT/US94/06008</p> <p>(22) International Filing Date: 27 May 1994 (27.05.94)</p> <p>(30) Priority Data: 08/068,522 27 May 1993 (27.05.93) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/068,522 (CIP) Filed on 27 May 1993 (27.05.93)</p> <p>(71) Applicant (for all designated States except US): CAMBRIDGE NEUROSCIENCE, INC. [US/US]; Building 700, One Kendall Square, Cambridge, MA 02139 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DURANT, Graham, J. [GB/US]; 55 Captain Luther Little Waye, Marshfield, MA 02050 (US). MAGAR, Sharad [IN/US]; 303 Lowell Street, #14, Somerville, MA 02145 (US). HU, Lain-Yen [-/US]; #16 Old Stagecoach Road, Bedford, MA (US).</p>	<p>(74) Agents: CONLIN, David, G. et al.; Dike, Bronstein, Roberts & Cushman, 130 Water Street, Boston, MA 02109 (US).</p> <p>(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, TJ, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: THERAPEUTIC SUBSTITUTED GUANIDINES</p> <p>(57) Abstract</p> <p>The present invention provides therapeutically useful substituted guanidines of formula (I) and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.</p> <div style="text-align: center;"> <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

THERAPEUTIC SUBSTITUTED GUANIDINES

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to certain substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such guanidines.

2. Background

A number of substituted guanidines have been reported. See, e.g., U.S. Patent Nos. 1,411,731, 1,422,506, 1,597,233, 1,642,180, 1,672,431, 1,730,388, 1,756,315, 1,795,739, 1,850,682, 2,145,214, 2,254,009, 2,633,474, 3,117,994, 3,140,231, 3,159,676, 3,228,975, 3,248,426, 3,252,816, 3,283,003, 3,270,054, 3,301,755, 3,320,229, 3,301,775, 3,409,669, 3,479,437, 3,547,951, 3,639,477, 3,681,457, 3,769,427, 3,784,643, 3,803,324, 3,908,013, 3,949,089, 3,975,533, 3,976,787, 4,060,640, 4,014,934, 4,161,541, 4,709,094, 4,906,779, 5,093,525, 5,190,976 and 5,262,568; PCT applications WO 90/12575, WO 91/12797, WO 91/18868, and WO 92/14697; and H.W. Geluk, et al., *J. Med. Chem.*, 12:712 (1969).

20

The amino acid L-glutamate is widely thought to act as a chemical transmitter substance at excitatory synapses within the central nervous system. Neuronal responses to glutamate are complex and appear to be mediated by at least three different receptor types, i.e., KA, QA and NMDA subtypes, each being named for their relatively specific ligands, i.e., kainic acid, quisqualic acid and N-methyl-D-aspartic acid,

25

respectively. An amino acid which activates one or more of these receptor types is referred to as an excitatory amino acid (EAA).

The NMDA subtype of excitatory amino acid receptors is
5 activated during normal excitatory synaptic transmission in the brain. Activation of NMDA receptors under normal conditions is responsible for the phenomena of long-term potentiation, a memory-like phenomenon, at excitatory synapses. Excessive excitation of neurons occurs in epileptic seizures and it has been shown that over-activation of NMDA
10 receptors contributes to the pathophysiology of epilepsy.

NMDA receptors are also strongly involved in nerve cell death which occurs following brain or spinal chord ischemia. Upon the occurrence of ischemic brain insults such as stroke or heart attack, an
15 excessive release of endogenous glutamate occurs, resulting in the over-stimulation of NMDA receptors. Associated with the NMDA receptors is an ion channel. The recognition site, i.e., the NMDA receptor, is external to the ion channel. When glutamate interacts with the NMDA receptor, it causes the ion channel to open, thereby permitting a flow of
20 cations across the cell membrane, e.g., Ca^{2+} and Na^{+} into the cell and K^{+} out of the cell. It is believed that this flux of ions, especially the influx of Ca^{2+} ions, caused by the interaction of glutamate with the NMDA receptor, plays an important role in nerve cell death. See, e.g., S.M. Rothman, et al., *Trends in Neurosci.*, 10(7):299-302 (1987).

25

Agents which block responses to NMDA receptor activation therefore have therapeutic uses in the treatment of neurological disorders such as epilepsy and also in the prevention of nerve cell death

resulting from hypoxia or hypoglycemia or following brain ischemia which occurs during stroke, trauma and heart attack. A number of disorders of the nervous system are associated with neurodegeneration that may be caused by overactivation of NMDA receptors. Antagonists of NMDA receptor-mediated responses have potential therefore for the treatment of such disorders as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome and Korsakoff's disease.


Research on the NMDA receptor-ion channel complex has led to determination of a receptor site within the ion channel known as the PCP receptor. See J.P. Vincent, et al., *Proc. Natl. Acad. Sci. USA*, 76:4678-4682 (1979); S.R. Zukin, et al., *Proc. Natl. Acad. Sci. USA*, 76:5372-5376 (1979); M.S. Sonders, et al., *Trends in Neurosci.*, 11(1):37-40 (1988); and N.A. Anis, et al., *Br. J. Pharmacol.*, 79:565-575 (1983). A compound which binds to the PCP receptor can act as an ion channel blocker, thereby interrupting the flow of ions through the cell membrane. In this manner, agents which interact with the PCP receptor act as non-competitive antagonists reducing the agonist action of glutamate at the NMDA receptor.

Known PCP receptor ligands include PCP, i.e., Phencyclidine, analogues such as 1-[1-(2-thienyl)-cyclohexyl]-piperidine (TCP), benzomorphan (sigma) opiates, and (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5,10-imine (i.e., the drug MK-801, see U.S. Patent No. 4,399,141). See, also, E.H.F. Wong, et al., *Proc. Natl. Acad. Sci. USA*, 83:7104-7108 (1986), and W.J. Thompson, et al., *J. Med. Chem.*, 33:789-808 (1990).

SUMMARY OF THE INVENTION

The present invention provides substituted guanidines of Formula I:

5



10

wherein R, R¹ and R² are each independently hydrogen, substituted or unsubstituted alkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkenyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkynyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkoxy having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylthio having from 1 to about 20 carbon atoms, substituted or unsubstituted aminoalkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted carbocyclic aryl having at least about 6 ring carbon atoms, substituted or unsubstituted aralkyl having at least about 6 carbon ring atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to 8 ring members in each ring and from 1 to 3 hetero atoms;


25 R³ and R⁴ are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkenyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkynyl having from 2 to

about 20 carbon atoms, substituted or unsubstituted alkoxy having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylthio having from 1 to about 20 carbon atoms, substituted or unsubstituted aminoalkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted carbocyclic aryl having at least about 6 ring carbon atoms, or substituted or unsubstituted aralkyl having at least about 6 ring carbon atoms;

each R^5 substituent is independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkenyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkynyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkoxy having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylthio having from 1 to about 20 carbon atoms, substituted or unsubstituted aminoalkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted carbocyclic aryl having at least about 6 ring carbon atoms, or substituted or unsubstituted aralkyl having at least about 6 ring carbon atoms;

n is an integer of from 1 to 3; and pharmaceutically acceptable salts thereof.

In another aspect, the invention provides compounds of the following Formula II:



II

wherein R, R¹ and R² are each independently hydrogen, substituted or unsubstituted alkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkenyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkynyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkoxy having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylthio having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylsulfinyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylsulfonyl having from 1 to about 20 carbon atoms, substituted or unsubstituted aminoalkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted carbocyclic aryl having at least 6 ring carbon atoms, substituted or unsubstituted aralkyl having at least 6 ring carbon atoms, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R³, R⁴, and each R⁵ substituent are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkenyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkynyl having from 2 to about 20 carbon atoms, substituted or unsubstituted alkoxy having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylthio having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylsulfinyl having from 1 to about 20 carbon atoms, substituted or unsubstituted alkylsulfonyl having from 1 to about 20 carbon atoms, substituted or unsubstituted aminoalkyl having from 1 to about 20 carbon atoms, substituted or unsubstituted carbocyclic aryl having about 6 or more ring carbon atoms, or substituted or unsubstituted aralkyl having about 6 or more ring carbon

atoms; n is an integer of from 0-3; or a pharmaceutically acceptable salt thereof. Thus, Formula II is defined the same as above for Formula I except R, R¹, R², R³, R⁴, R⁵ of Formula II each also may be independently selected from substituted or unsubstituted alkylsulfoxide
5 having from 1 to about 20 carbon atoms and substituted or unsubstituted alkylsulfonyl having from 1 to about 20 carbon atoms.

Preferred compounds of Formulas I and II exhibit a high affinity for the PCP receptor. The phrase "high affinity for the PCP receptor" as
10 used herein means the compound exhibits an IC₅₀ of 1 μ M or less in a typical PCP receptor binding assay such as described in Example 74 which follows, more preferably an IC₅₀ of 0.5 μ M or less in such a PCP receptor assay. For reasons discussed below, for at least some therapeutic applications, further preferred are those compounds of
15 Formulas I and II that exhibit such high affinity for the PCP receptor as well as high affinity for the sigma receptor. The phrase "high affinity for the sigma receptor" as used herein means the compound exhibits an IC₅₀ of 1 μ M or less in a typical sigma receptor binding assay such as described in Example 75 which follows, more preferably an IC₅₀ of 0.5
20 μ M or less in such a sigma receptor assay.

The substituted guanidines of the invention are useful for a number of therapeutic applications. Accordingly, the present invention includes methods for treatment and/or prophylaxis of neurological
25 conditions such as epilepsy, neurodegenerative conditions and/or nerve cell death resulting from e.g. hypoxia, hypoglycemia, brain or spinal chord ischemia, brain or spinal chord trauma, and the like. Compounds of Formulas I and II also are useful to treat and/or prevent various

neurodegenerative diseases such as Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome and Korsakoff's disease. The methods of the invention in general comprise administration of a therapeutically effective amount of one or more compounds of Formula I of Formula II to an animal, including a mammal, particularly a human.

The invention also provides pharmaceutical compositions that comprise one or more compounds of Formula I or Formula II and a suitable carrier.

Other aspects of the invention are disclosed *infra*.

DETAILED DESCRIPTION OF THE INVENTION

Suitable halogen substituent groups of compounds of Formulas I and II as defined above (i.e. compounds of the invention) include F, Cl, Br and I. It is intended that references herein to Formulas I and II, or references to compounds of the invention, apply equally to compounds of Formulas Ia, Ib, Ic, IIa, IIb and IIc as those formulas are defined herein. Hence, suitable and preferred substituent groups of Formulas I and II as identified herein, are also suitable and preferred substituent groups of compounds of Formulas Ia, Ib, Ic, IIa, IIb and IIc. Alkyl groups of compounds of Formulas I and II preferably have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Methyl, ethyl and propyl including isopropyl are particularly preferred alkyl groups. As used herein, the term alkyl unless otherwise modified refers to both cyclic and noncyclic groups, although

of course cyclic groups will comprise at least three carbon ring members. Straight or branched chain noncyclic alkyl groups are generally more preferred than cyclic groups. Preferred alkenyl and alkynyl groups of compounds of the invention have one or more

5 unsaturated linkages and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are

10 generally more preferred. Preferred alkoxy groups of compounds of Formulas I and II include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Preferred alkylthio groups of

15 compounds of Formulas I and II include those groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfinyl groups of

20 compounds of the invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfinyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfonyl groups

25 of compounds of the invention include those groups having one or more sulfonyl (SO₂) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4

carbon atoms are particularly preferred. Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms.

Secondary and tertiary amine groups are generally more preferred than primary amine moieties. Suitable heteroaromatic groups of compounds of Formula I and Formula II contain one or more N, O or S atoms and include, e.g., coumarinyl including 8-coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl and benzothiazol. Suitable heteroalicyclic groups of compounds of Formula I and Formula II contain one or more N, O or S atoms and include, e.g., tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino and pyrrolindinyl groups.

Suitable carbocyclic aryl groups of compounds of Formula I and Formula II include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical carbocyclic aryl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Specifically preferred carbocyclic aryl groups include phenyl including 3-substituted phenyl, 2,5-substituted phenyl, 2,3,5-substituted and 2,4,5-substituted phenyl, particularly where the phenyl substituents are independently selected from the same group as defined above for R³-R⁵; naphthyl including 1-naphthyl and 2-naphthyl; biphenyl; phenanthryl; and anthracyl. Suitable aralkyl groups of compounds of Formula I and Formula II include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms.

Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH₂-naphthyl).

Said substituted R, R¹, R², R³, R⁴ and R⁵ groups of Formula I or
5 Formula II (as well as substituted groups of Formulas Ia-Ic and IIa-IIc as specified below) may be substituted at one or more available positions by one or more suitable groups such as, e.g., halogen such as fluoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; azido; alkanoyl such as a
C₁₋₆ alkanoyl group such as acyl and the like; carboxamido; alkyl groups
10 including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having those having one or more oxygen linkages
15 and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; and aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon
20 atoms or from 1 to about 6 carbon atoms.

It should be understood that alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl and aminoalkyl substituent groups described above include groups where a hetero atom is directly bonded to a ring system, such as
25 a carbocyclic aryl group or a heterocyclic group, as well as groups where a hetero atom of the group is spaced from such ring system by an alkylene linkage, e.g. of 1 to about 4 carbon atoms.

Preferred phenyl ring substituents R^3 , R^4 and R^5 of Formulas I and II (as well as phenyl ring substituents of Formulas Ia-Ic and IIa-IIc as specified below) include halogen, particularly F, Cl and Br, hydroxyl, azido, substituted or unsubstituted alkyl including halogenated alkyl, substituted and unsubstituted alkoxy including halogenated alkoxy, and substituted and unsubstituted alkylthio. Typically preferred phenyl ring substituents have 1 to 4 carbon atoms with methyl, ethyl, and propyl including isopropyl being particularly preferred. Halogen-substituted alkyl and alkoxy groups are also particularly preferred including fluoroalkyl having 1, 2, 3 or 4 carbon atoms such as trifluoromethyl and fluoro-substituted alkoxy having 1, 2, 3 or 4 carbon atoms such as trifluoromethoxy ($-\text{OCF}_3$). Methylthio ($-\text{SCH}_3$) and ethylthio ($-\text{SCH}_2\text{CH}_3$) are also particularly preferred phenyl ring substituents.

Preferred compounds of the invention include trisubstituted compounds where one of the guanidine substituents R , R^1 and R^2 of the above defined Formulas (or the corresponding guanidine substituents of Formulas Ia-Ic and IIa-IIc as specified below) is hydrogen and the other two substituents are other than hydrogen, more preferably where R or R^1 is heterocyclic aryl or carbocyclic aryl, still more preferably where R is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl and one of R^1 and R^2 is hydrogen and one of R^1 and R^2 is substituted or unsubstituted alkyl. Also preferred are N,N' -disubstituted compounds, i.e. where one of R and R^1 of Formulas I or II (or the corresponding guanidine substituents of Formulas Ia-Ic and IIa-IIc) is hydrogen and R^2 is hydrogen, preferably where R is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl and R^1 and R^2 are hydrogen. Also preferred are


N,N,N',N'-tetrasubstituted compounds, i.e. where each of R, R¹ and R² substituents of Formulas I or II (or the corresponding guanidine substituents of Formulas Ia-Ic and IIa-IIc) is other than hydrogen, preferably where R or R¹ is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl, more preferably where R is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl and R¹ and R² are each substituted or unsubstituted alkyl. In any event, at least one of the substituents R and R¹ of compounds of Formula I or II generally will be other than hydrogen.

Preferred R³, R⁴ and R⁵ alkylsulfinyl groups of compounds of Formula II (as well as phenyl ring alkylsulfinyl groups of compounds of Formulas IIa-IIc as specified below) typically have one or more sulfoxide groups, more typically, one or two sulfoxide groups and from 1 to about 8 carbon atoms, more preferably 1 to about 6 carbon atoms, even more preferably 1 to about 3 carbon atoms. Methylsulfinyl (-S(O)CH₃) and ethylsulfinyl (-S(O)CH₂CH₃) are particularly preferred R³, R⁴ and R⁵ alkylsulfinyl groups. Preferred substituted alkylsulfinyl groups include haloalkylsulfinyl groups that contain one or more F, Cl, Br or I atoms, preferably one or more F atoms, and preferably 1 to about 3 carbon atoms, more preferably one or two carbon atoms. Specifically preferred groups include fluoromethylsulfinyl, particularly trifluoromethylsulfinyl (-S(O)CF₃), and fluoroethylsulfinyl such as 2-trifluoroethylsulfinyl (-S(O)CH₂CF₃) and pentafluoroethylsulfinyl (-S(O)CF₂CF₃).

Preferred R³, R⁴ and R⁵ alkylsulfonyl ring substituents of compounds of Formula II (as well as phenyl ring alkylsulfonyl groups of

compounds of Formulas IIa-IIc as specified below) have one or more sulfono (SO_2) groups, more typically one sulfono group, and from 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1 to about 3 carbon atoms. Methylsulfonyl ($-\text{S}(\text{O})_2\text{CH}_3$) and ethylsulfonyl ($-\text{S}(\text{O})_2\text{CH}_2\text{CH}_3$) are particularly preferred R^3 and R^4 sulfonoalkyl groups. Preferred substituted alkylsulfonyl groups include haloalkylsulfonyl groups that contain one or more F, Cl, Br or I atoms, preferably one or more F atoms, and preferably 1 to about 3 carbon atoms, more preferably one or two carbon atoms. Specifically preferred groups include fluoromethylsulfonyl, particularly trifluoromethylsulfonyl ($-\text{S}(\text{O})_2\text{CF}_3$), and fluoroethylsulfonyl such as 2-trifluoroethylsulfonyl ($-\text{S}(\text{O})_2\text{CH}_2\text{CF}_3$) and pentafluoroethylsulfonyl ($-\text{S}(\text{O})_2\text{CF}_2\text{CF}_3$).

Particularly preferred R and R^1 groups include phenyl substituted at least at the 2,5 ring positions. For example, preferred are the following compounds of Formula Ia:



wherein R and R^2 are the same as defined above for Formula I; each R^3 , R^4 , R^5 , $\text{R}^{3'}$, $\text{R}^{4'}$, and $\text{R}^{5'}$ substituent is independently selected from the same group of substituents as defined above for R^3 - R^5 for Formula I; m and n are each independently an integer of from 0 to 3; and pharmaceutically acceptable salts thereof. Preferred compounds of


Formula Ia include those compounds where at least one of R and R² is other than heterocyclic aryl or carbocyclic aryl, e.g. where at least one of R and R² is hydrogen or substituted or unsubstituted alkyl, particularly, substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms. Preferred values of m and n of Formula Ia are 0 and 1.

Also preferred are compounds of Formula IIa, defined the same as for Formula Ia above, but where each substituent, particularly the R³, R⁴, R⁵, R^{3'}, R^{4'}, and R^{5'} substituents, may be independently alkylsulfinyl having from 1 to about 20 carbon atoms or alkylsulfonyl having from 1 to about 20 carbon atoms. Preferred compounds of Formula IIa include those compounds where at least one of R and R² is other than heterocyclic aromatic or carbocyclic aryl, e.g. where at least one of R and R² is hydrogen or substituted or unsubstituted alkyl, particularly, substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms. Preferred values of m and n of Formula IIa are 0 and 1.

Further preferred compounds of Formula I include those compounds where the value n equals 1, particularly where n equals 1 and the phenyl ring is substituted by a R⁵ group at the 3- or 4-position, i.e. the phenyl ring is 2,3,5-substituted or 2,4,5-substituted.

Such compounds of Formula II are also preferred, i.e. compounds of Formula II where the value n equals 1, particularly where n equals 1 and the phenyl ring is substituted by a R⁵ group at the 3- or 4-position, i.e. the phenyl ring is 2,3,5-substituted or 2,4,5-substituted.

Especially preferred compounds of Formula I are those where n is equal to zero (i.e., the 3, 4 and 6 positions of the phenyl ring are hydrogen-substituted), specifically compounds of the following Formula Ib:



Ib

where the groups R through R⁴ are the same as specified above for Formula I; and pharmaceutically acceptable salts thereof. Particularly preferred compounds of Formula Ib include those compounds where R is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl such as substituted or unsubstituted phenyl or naphthyl and where at least one of R¹ and R² is other than heterocyclic aryl or carbocyclic aryl, e.g. where at least one of R¹ and R² is hydrogen or substituted or unsubstituted alkyl, particularly substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms.


Also preferred are compounds of Formula IIb, defined the same as for Formula Ib above, but where each substituent, particularly the R³ and R⁴ substituents, may be independently alkylsulfinyl having from 1 to about 20 carbon atoms or alkylsulfonyl having from 1 to about 20 carbon atoms. Particularly preferred compounds of Formula IIb include those compounds where R is substituted or unsubstituted heterocyclic aryl or substituted or unsubstituted carbocyclic aryl such as substituted or unsubstituted phenyl or naphthyl and where at least one of R¹ and R²

is other than heterocyclic aryl or carbocyclic aryl, e.g. where at least one of R^1 and R^2 is hydrogen or substituted or unsubstituted alkyl, particularly substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms.

5

A still further group of preferred compounds of the invention have, in addition to a 2,5-substituted phenyl moiety, at least one guanidine substituent (i.e., R, R^1 or R^2 of Formulas I or II) that is a phenyl group substituted at the 3-position, preferably without
 10 substitution at other ring positions. Particularly preferred are N-(3-substituted phenyl)-N'-(2,5-disubstituted phenyl)guanidines of the following Formula Ic:

15



20

wherein R and R^2 are the same as defined above for Formula I; each $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{3''}$ substituent is independently selected from the same group of substituents as defined above for R^3 , R^4 and R^5 for Formula I; and n is an integer of from 0 to 3; and pharmaceutically salts of said
 25 compounds. Preferred compounds of Formula Ic include those compounds where at least one of R and R^2 is other than heterocyclic aryl or carbocyclic aryl, e.g. where at least one of R and R^2 is hydrogen or substituted or unsubstituted alkyl, particularly substituted or

unsubstituted alkyl having 1 to about 4 carbon atoms. Especially preferred are compounds of Formula Ic are those where one of R and R² is hydrogen and the other is substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms, more preferably where R is methyl, ethyl or propyl and R² is hydrogen. Preferred values of n of Formula Ic are 0 and 1.

Also preferred are compounds of Formula IIc, defined the same as for Formula Ic above, but where each substituent, particularly the R^{3'}, R^{4'}, R^{5'} and R^{3''} substituents, also may be independently alkylsulfinyl having from 1 to about 20 carbon atoms or alkylsulfonyl having from 1 to about 20 carbon atoms. Preferred compounds of Formula IIc include those compounds where at least one of R and R² is other than heterocyclic aryl or carbocyclic aryl, e.g. where at least one of R and R² is hydrogen or substituted or unsubstituted alkyl, particularly substituted or unsubstituted alkyl having 1, 2, 3 or 4 carbon atoms. Especially preferred are compounds of Formula IIc are those where one of R and R² is hydrogen and the other is substituted or unsubstituted alkyl having 1 to about 4 carbon atoms, more preferably where R is methyl, ethyl or propyl and R² is hydrogen. Preferred values of n of Formula IIc are 0 and 1.

Preferred compounds of Formulas I and II exhibit high affinity to the PCP receptor. For at least some therapeutic applications, use of compounds of Formulas I or II that exhibit high affinity to both the PCP receptor and the sigma receptor may be preferred. While not wishing to be bound by theory, it is thought that an agent that has high affinity to both the PCP and sigma receptors can provide effective therapy for the

indications mentioned above without the risk of vacuolar injury as exhibited by some prior NMDA receptor antagonists. See, e.g., Olney et al., *Science*, **244**:1360-1364 (1989).

- 5 Without wishing to be bound by theory, compounds of the invention that contain an alkylsulfinyl and/or alkylsulfonyl group, may be, in effect, "pro-drugs" wherein after administration of the compound to a subject the sulfinyl or sulfonyl group(s) are metabolized (reduced) *in vivo* to the corresponding sulfide moiety. In particular, compounds of
- 10 the invention that have an aryl substituent that is ring-substituted by one or more alkylsulfinyl and/or alkylsulfonyl group(s) may be effective pro-drugs. Thus, preferred compounds of Formula II include those containing a carbocyclic or heterocyclic group, such as a naphthyl or phenyl group, substituted by one or more alkylsulfinyl or alkylsulfonyl
- 15 groups having from 1 to about 4 carbon atoms.

Specifically preferred compounds of the present invention include:

- N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
20 N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)-N'-methylguanidine;
N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,5-dibromophenyl)-N'-methylguanidine;
N-(3-ethylphenyl)-N'-(2,5-dibromophenyl)guanidine;
25 N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;

- N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
- 5 N-(3-ethylphenyl)-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
- 10 N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-fluoro-5-ethylphenyl)guanidine;
- 15 N-(3-ethylphenyl)-N-methyl-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-methylphenyl);
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
- 20 N-(3-ethylphenyl)-N'-(2-chloro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-methylthio)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-methylthio)guanidine;
N-(1-naphthyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-ethylphenyl)guanidine;
- 25 N-(1-naphthyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,4,5-trichlorophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,4,5-trichlorophenyl)guanidine;

- N-(3-ethylphenyl)-N-methyl-N'-(2,3,5-trichlorophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,3,5-trichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2,4,5-trichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2,3,5-trichlorophenyl)guanidine;
5 N-(1-naphthyl)-N'-(2,5-dichlorophenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2-chloro-5-methylphenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dimethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-methylphenyl)-N'-methylguanidine;
10 N-(1-naphthyl)-N'-(2,5-dimethylphenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)-N-methylguanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2-chloro-5-thiomethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
15 N-(1-naphthyl)-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-thiomethyl-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-methoxy-5-methylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
20 N-(1-naphthyl)-N'-(2-chloro-5-ethylphenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-methyl-N'-(2-chloro-5-thiomethylphenyl)guanidine;
N-(8-quinoliny)-N'-(2-chloro-5-methylphenyl)guanidine;
N-(8-quinoliny)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(8-quinoliny)-N'-methyl-(2-chloro-5-ethylphenyl)guanidine;
25 N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-
methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-
methylthiophenyl)guanidine;

- N-(3-methylthiophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
5 N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2,5-dichlorophenyl)guanidine;
10 N-(3-methylthiophenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-
15 methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-
methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-
20 ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-
ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-
25 ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-
ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;

- N-(3-trifluoromethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
5 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
10 N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-
methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-
methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
15 N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-
methylthiophenyl)guanidine;
20 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-
methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-bromophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-bromophenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
25 N-(3-bromophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-methyl-N'-(2,5-
dibromophenyl)guanidine;

- N-(3-trifluoromethoxyphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
5 N-(3-trifluoromethoxyphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylsulfonylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfonylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfonylphenyl)-N'-(2,5-dibromophenyl)guanidine;
10 N-(3-methylsulfinylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfinylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfinylphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-iodophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-iodophenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
15 N-(3-iodophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-iodophenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-iodophenyl)-N'-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-iodophenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
20 N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
25 N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;

- N-(3-methylthiophenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
5 N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
10 N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
15 N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
20 N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
25 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;

- N-(3-ethylphenyl)-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
5 N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
10 N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
15 N-(3-methylthiophenyl)-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
20 N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
25 N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

- N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethyl
thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-trifluoromethyl
thiophenyl)guanidine;
5 N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethyl
thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethyl
thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethyl
10 thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-trifluoromethyl
thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethyl
thiophenyl)guanidine;
15 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethyl
thiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethyl
thiophenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
20 N-(1-naphthyl)-N'-(2-iodo-5-methylthiophenyl)guanidine;
N-(1-naphthyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
and pharmaceutically acceptable salts of said compounds.

- Also specifically preferred are compounds specifically identified
25 above and having one or more additional guanidine substituents (i.e., R,
R¹ or R² substituents of Formulas I or II) that are other than hydrogen,
particularly one or more additional substituents that are substituted or
unsubstituted alkyl, especially unsubstituted methyl, ethyl, propyl, butyl,

pentyl or hexyl, more preferably unsubstituted methyl, ethyl or propyl. For example, tetra-substituted compounds are particularly preferred such as di-alkyl-, di-aryl-substituted compounds such as N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2,5-dibromophenyl)guanidine, N-(3-ethylphenyl)-N,N'-
5 dimethyl-N'-(2-chloro-5-trifluoromethylphenyl)guanidine, and the like.

In a further aspect, the invention provides compounds of Formula II', which Formula II' is defined the same as Formula II above but where each of the substituents R³, R⁴ and each R⁵ also may be independently
10 nitro, cyano, substituted or unsubstituted alkanoyl or substituted or unsubstituted carboxyl. Suitable and preferred substituents of compounds of Formula II as disclosed herein are also suitable and preferred substituents of Formula II'. Suitable alkanoyl groups of Formula II' have 1 to about 8 carbon atoms, more preferably 1 to about
15 4 carbon atoms. Acyl is a particularly suitable alkanoyl group. Carboxyl groups of Formula II' include acid and ester groups of the formula $-(CH_2)_nCOOY$ where n is an integer equal to 0 to about 8, more preferably 1, 2, 3 or 4, and Y is hydrogen or substituted or unsubstituted alkyl, preferably have 1 to about 6 carbon atoms, or 1 to
20 about 3 carbon atoms. Compounds of Formula II' can be prepared as disclosed herein for synthesis of compounds of Formulas I and II. The invention also includes use of compounds of Formula II' for the methods of treatment disclosed herein, in the same manner as described for Formulas I and II.

25

Compounds of Formulas I and II can be readily prepared by the reaction of an amine, typically an amine salt such as an amine hydrochloride, with a preformed alkyl or aryl cyanamide (see S.R. Safer,

et al., *J. Org. Chem.*, **13**:924 (1948)) or the corresponding N-substituted alkyl or aryl cyanamide. This is a particularly suitable method for producing N,N'-diaryl-N'-alkyl guanidines in which the substituents are not identical. For a synthesis of asymmetrical

5 guanidines, see G.J. Durant, et al., *J. Med. Chem.*, **28**:1414 (1985), and C.A. Maryanoff, et al., *J. Org. Chem.*, **51**:1882 (1986), incorporated by reference herein. For additional discussion of guanidine synthesis, see PCT application WO 91/12797 and U.S. Patents Nos. 5,093,525, 5,262,568 and 5,265,568, all incorporated by reference

10 herein. See also H.W.J. Cressman, *Org. Syn. Coll.*, **3**:608-609 (1955); M.P. Kavanaugh, et al., *Proc. Natl. Acad. Sci. USA*, **85**:2844-2848 (1988); and E. Weber, et al., *Proc. Natl. Acad. Sci. USA*, **83**:8784-8788 (1986), all incorporated herein by reference.

15 More particularly, compounds of Formulas I and II can be prepared suitably by reaction of an appropriate amine salt such as an amine hydrochloride with a slight molar excess (e.g., ca. 1.1 molar equivalent) of a substituted cyanamide in a suitable solvent such as toluene or chlorobenzene under an inert atmosphere such as argon or nitrogen.

20 The reaction solution is then heated from about 110° to 120°C for 2 to about 16 hours until reaction completion, e.g. as indicated by thin layer chromatography. The reaction solution is then cooled to room temperature, and then preferably diluted with a solvent such as absolute alcohol. The solvent is then removed under reduced pressure to provide

25 the desired substituted guanidine. The crude product then can be purified by recrystallization and/or flash chromatography, e.g. by elution on silica gel (60-200 mesh, 50x w/w) with 5-25% methanol in ethyl acetate. Suitable recrystallization solvents include an ethanol/ethyl

acetate mixture or an ethanol/ether mixture. The cyanamide and amine reagents with appropriate substituents (i.e., R, R¹, R² and R³, R⁴, R⁵-substituted phenyl substituents), are commercially available or can be readily prepared by known procedures. For example, the cyanamide

5 starting material can be synthesized from the correspondingly substituted amine by treatment with cyanogen bromide (BrCN) in suitable solvent such as dry ethyl ether. The amine hydrochloride can be obtained by treatment of an appropriate amine with an excess of HCl. For example, a 2,5-substituted aniline hydrochloride salt can be

10 prepared by adding methanolic HCl to a cooled solution of the substituted aniline and then stirring at room temperature for about 30 minutes. An alkylsulfinyl-substituted or alkylsulfonyl-substituted reagent, that can provide correspondingly substituted compounds of the invention as described above, can be provided by oxidation (e.g., H₂O₂)

15 of alkylthio-substituted reagents. See, for instance, Example 5 which follows.

As discussed above, the present invention includes methods for treating or preventing certain neurological disorders, including the

20 consequences of stroke or traumatic brain injury, epilepsy or neurodegenerative diseases comprising the administration of an effective amount of one or more guanidines of Formulas I or II to a subject including a mammal, particularly a human, in need of such treatment. In particular, the invention provides methods for treatment and/or

25 prophylaxis of nerve cell death resulting e.g. from hypoxia, hypoglycemia, brain or spinal cord ischemia, brain or spinal cord trauma, stroke, heart attack or drowning. Typical candidates for treatment include e.g. heart attack, stroke, brain or spinal cord injury patients,

patients undergoing major surgery such as heart surgery where brain ischemia is a potential complication and patients such as divers suffering from decompression sickness due to gas emboli in the blood stream.

5 In particular, the invention provides methods for treatment which comprise administration of one or more compounds of the invention to a patient that is undergoing surgery or other procedure where brain or spinal cord ischemia is a potential risk. For example, carotid endarterectomy is a surgical procedure employed to correct
10 atherosclerosis of the carotid arteries. Major risks associated with the procedure include intraoperative embolization and the danger of hypertension in the brain following increased cerebral blood flow, which may result in aneurism or hemorrhage. Thus, an effective amount of one or more compounds of the present invention could be administered
15 pre-operatively or peri-operatively to reduce such risks associated with carotid endarterectomy.

 The present invention further includes methods for prophylaxis against neurological deficits resulting from coronary artery bypass grafts
20 and aortic valve replacement surgery. Those methods will comprise administering to a patient undergoing such surgical procedures an effective amount of one or more compounds of the invention, typically either pre-operatively or peri-operatively.

25 The present invention also provides methods for prophylaxis against neurological injury for patients undergoing myocardial infarction, a procedure that can result in ischemic insult to the patient. Such methods will comprise administering to a patient undergoing such

surgical procedure an effective amount of one or more compounds of the invention, typically either pre-operatively or peri-operatively.

Also provided are methods for treating or preventing neuropathic pain such as may experienced by cancer patients, persons having diabetes, amputees and other persons who may experience neuropathic pain. These methods for treatment comprise administration of an effective amount of one or more compounds of Formulas I or II to a patient in need of such treatment.

10

Further provided are methods of ameliorating the neurotoxic effect induced by glutamate interacting with the NMDA receptor of a nerve cell, comprising administering to a subject, such as a mammal, particularly a human, exhibiting symptoms of or susceptible to such neurotoxic effect, one or more compounds of Formulas I or II in an amount effective to ameliorate the neurotoxic effect.

15

This invention also provides methods of inhibiting NMDA receptor-ion channel related neurotoxicity comprising administering to a subject in need thereof such as a mammal, particularly a human, one or more compounds of Formulas I or II in an amount effective to inhibit or prevent the neurotoxicity.

20

The invention further provides a method of treating Korsakoff's disease, a chronic alcoholism-induced condition, comprising administering to a subject including a mammal, particularly a human, one or more compounds of Formula I or Formula II in an amount effective to treat the disease. Pretreatment of animals with the NMDA

25

antagonist MK-801 (Merck Index, monograph 3392, 11th ed., 1989) markedly attenuates the extent of cell loss, hemorrhages and amino acid changes in a rat model of Korsakoff's disease. See P.J. Langlais, et al., *Soc. Neurosci. Abstr.*, 14:774 (1988). Therefore, compounds of the

5 present invention have utility for the attenuation of cell loss, hemorrhages and amino acid changes associated with Korsakoff's disease.

The invention also provides methods for determining binding

10 activity of compounds of the invention, e.g. binding activity to NMDA receptors, as well as *in vitro* and *in vivo* binding activity diagnostic methods using one or more radiolabelled compounds of Formula I or Formula II, e.g., a compound of the invention that is labeled with ^{125}I , tritium, ^{32}P , ^{99}Tc , or the like, preferably ^{125}I . For instance, a compound

15 of the invention having a phenyl substituent that is ring substituted with one or more ^{125}I groups can be administered to a mammal and the subject then scanned for binding of the compound to NMDA receptors. Specifically, single photon emission computed tomography ("SPECT") can be employed to detect such binding. Such an analysis of the

20 mammal could e.g. aid in the diagnosis and treatment of acute cerebral ischemia.

Accordingly, the invention includes compounds of Formula I or II that contain a radiolabel such as ^{125}I , tritium, ^{32}P , ^{99}Tc , or the like,

25 preferably ^{125}I . Such radiolabelled compounds can be suitably prepared by procedures known in the synthesis art. For example, a compound of the invention having an aromatic group, such as phenyl, that has a bromo or chloro ring substituent can be employed in an exchange

labeling reaction to provide the corresponding compound having an ^{125}I ring substituent.

Certain pharmacological activity of compounds of Formulas I and II can be determined by, e.g., a method involving: (a) determining the binding affinity with respect to the PCP receptor by competitive displacement of tritiated MK-801; (b) *in vitro* cytotoxicity studies measuring the ability of the compound to prevent nerve cell death caused by exposure to glutamate; and (c) determination of *in vivo* neuroprotective ability using animal models.

Evaluation of the binding activity of compounds of Formulas I and II with respect to the PCP receptor is suitably performed using radioligand binding assays. The compounds are tested to determine their ability to displace tritiated MK-801 which is used to label PCP receptors. Evaluating the competitive displacement binding data, the preferred compounds are those which exhibit a high affinity (i.e., low IC_{50} value) for the PCP receptors. Under such PCP binding activity studies, an IC_{50} value of at most about $1\ \mu\text{M}$, preferably at most about $0.5\ \mu\text{M}$, indicates a high binding affinity.

As discussed above, under sigma binding studies an IC_{50} value of less than $1\ \mu\text{M}$ indicates a high binding affinity of a compound to the sigma receptor. The sigma receptor binding assay, preferably against ^3H -DTG, may be performed as disclosed by E. Weber, et al., *Proc. Natl. Acad. Sci (USA)*, **83**:8784-8788 (1986), which is incorporated by reference herein.

Compounds of Formulas I and II may be used in therapy in conjunction with other medicaments. For example, for treatment of a stroke victim, one or more compounds of Formulas I or II may be suitably administered together with a pharmaceutical targeted for
5 interaction in the blood clotting mechanism such as streptokinase, tPA, urokinase and other agents that lyse clots.

As discussed above, preferred guanidines of Formulas I and II exhibit high affinity for the PCP receptor. Thus, in addition to the
10 treatment of neurodegeneration and related conditions discussed above, the guanidines of the present invention may also be used as a pharmacological tool in an animal model for the screening of potential PCP receptor ligands.

15 The compounds of this invention can be administered intranasally, orally or by injection, e.g., intramuscular, intraperitoneal, subcutaneous or intravenous injection, or by transdermal, intraocular or enteral means. The optimal dose can be determined by conventional means. Guanidines of the present invention are suitably administered to a
20 subject in the protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, etc.

25 The compounds of this invention can be employed, either alone or in combination with one or more other therapeutic agents as discussed above, as a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier

substances suitable for parenteral, enteral or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Ampules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.

Intravenous or parenteral administration, e.g., sub-cutaneous, intraperitoneal or intramuscular administration are preferred. The compounds of this invention are particularly valuable in the treatment of mammalian subjects, e.g., humans, wherein the pathophysiology of the disease involves excessive excitation of nerve cells by agonists of the NMDA receptor. Typically, such subjects include those afflicted with neurodegenerative diseases such as Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Alzheimer's disease, Down's Syndrome and Korsakoff's disease. Also suitable for treatment are those subjects suffering from or likely to suffer from nervous system dysfunctions resulting from, for example, epilepsy or nerve cell degeneration which is the result of hypoxia, hypoglycemia, brain or spinal chord ischemia or brain or spinal chord trauma. As discussed above, typical candidates for treatment include heart attack, stroke, brain or spinal cord injury patients, patients undergoing major surgery where brain or spinal cord ischemia is a potential complication and patients such as divers suffering from decompression sickness due to gas emboli in the blood stream.

It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines. In general, a suitable effective dose of one or more compounds of Formula I or Formula II, particularly when using the more potent

compound(s) of Formulas I or II, will be in the range of from 0.01 to 100 milligrams per kilogram of bodyweight of recipient per day, preferably in the range of from 0.01 to 20 milligrams per kilogram bodyweight of recipient per day, more preferably in the range of 0.05 to 4 milligrams per kilogram bodyweight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 4 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule. Such sub-doses may be administered as unit dosage forms, e.g., containing from 0.05 to 10 milligrams of compound(s) of Formula I or II per unit dosage, preferably from 0.2 to 2 milligrams per unit dosage.

As with prior guanidines such as those reported in U.S. Patent No. 1,411,713, the guanidines of the present invention should have utility as rubber accelerators.

The entire text of all applications, patents and publications cited above and below are incorporated by reference herein.

The following non-limiting examples are illustrative of the invention.

GENERAL COMMENTS

In the following examples, melting points (mp) were determined in open capillary tubes on a Thomas-Hoover apparatus (compounds melting < 230°C) and are uncorrected. The NMR spectra of all compounds were recorded on a General Electric QE-300 or Bruker 300, and chemical shifts are reported in ppm relative to the residual signal of the

- deuterated solvent (CHCl_3 , 7.26 ppm; HCD_2OD , 3.30 ppm; TMS, 0.00 ppm). IR spectra were recorded on a Nicolet 5DXB FT-IR, or a Perkin-Elmer model 1420 in CHCl_3 or neat. IR and NMR spectra of all compounds are consistent with their assigned structures. Elemental analyses were performed by M-H-W Laboratories (Phoenix, AZ), or Galbraith Laboratories (Knoxville, TN). 1-Naphthylamine, cyanogen bromide, 3-ethylaniline and chlorobenzene were obtained from Aldrich Chemical Company, and were used as received. All other solvents were reagent grade. 1-Naphthyl cyanamide that can be used to prepare compounds of Examples 27-46 and 51 is suitably prepared by the following procedure. To a solution of 20.0 g (140 mMol) 1-naphthylamine in ether at 0°C was added by cannulation a solution of 17.5 mL (87.5 mMol) BrCN (5.0 M in CH_3CN ; Aldrich). After 0.5 hours the cooling bath was removed and the mixture was stirred at room temperature overnight (14 hours). A crystalline precipitate of the amine $\cdot\text{HBr}$ was formed, which was filtered off under suction, and washed with ethyl acetate (15 mL x 3). The filtrate was concentrated in vacuo to provide 12.5 g of a purple colored solid of the crude cyanamide, whose TLC showed the presence of minor amounts of the hydrobromide amine salt. The crude solid was stirred with water (200 mL) for 1 hour, after which filtration under suction left a pinkish solid which was dried in a vacuum oven overnight to afford 9.2 g, (78.3%) of the pure 1-naphthyl cyanamide.
- EXAMPLE 1** - Preparation of N-(3-ethylphenyl)-N-methyl-N'-2,5-dichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of $\text{R} = 3\text{-ethylphenyl}$, $\text{R}^1 = \text{CH}_3$, $\text{R}^2 = \text{H}$, $\text{R}^3 = \text{R}^4 = \text{Cl}$, $n = 0$).

Part 1: Preparation of N-(3-ethylphenyl)-N-methylcyanamide

Step A: 3-ethylphenylcyanamide

A solution of cyanogen bromide (11.36 g, 107 mmol) in anhydrous diethylether (50 mL) was added slowly to a stirred solution of
5 3-ethylaniline (20.8 g, 171 mmol) in diethylether at 4°C. After the addition, the reaction mixture was stirred at 24°C for 12 hours and it became a brown solution with a white precipitate. The precipitate was filtered off; the filtrate was washed with aqueous HCl (1N, 3 x 150 mL) and brine (60 mL). Then the etherate solution was dried over MgSO₄,
10 filtered, and concentrated to yield a thick liquid. The crude product was further purified by chromatography (SiO₂, hexanes, hexanes/CH₂Cl₂, CH₂Cl₂) to afford 3-ethylphenylcyanamide (11.6 g, 76% in yield) as a liquid.

Step B: N-(3-ethylphenyl)-N-methylcyanamide

15 A suspension of 3-ethylphenylcyanamide (4.65 g, 31.8 mmol) and sodium hydride (2.55 g of 80% NaH in mineral oil suspension, 63.6 mmol of NaH) in dried THF was heated at reflux for 3 hours. The reaction mixture was cooled in an ice bath and methyl iodide (11.28 g, 79.5 mmol) was added dropwise with stirring to the mixture. The
20 reaction mixture was then allowed to stir for 15 hours, followed by the successive addition of MeOH (10 mL). The reaction mixture was then concentrated to dryness to give the crude product. Distilled water (40 mL) was added to this crude product and the aqueous mixture and was extracted with CH₂Cl₂ (4 x 40 mL). The combined organic extracts
25 were washed with water (3 x 30 mL) and then dried over MgSO₄. The solvent was removed to afford the crude product as an amber syrup. Flash chromatography (SiO₂, CH₂Cl₂) of the crude product afforded 4.2 g (75% yield) of the desired product.

Part 2: Preparation of 2,5-Dichloroaniline Hydrochloride

To a solution of 2,5-dichloroaniline (Aldrich, 1.5 g, 9 mmol) in methanol (10 mL) was added methanolic HCl (1M, 30 mL) at 4°C, then the reaction mixture was stirred at 25°C for 30 minutes. The resulting solution was then evaporated and dried under vacuum to afford 1.6 g of 2,5-dichloroaniline hydrochloride (88% yield).

Part 3: Guanidine Synthesis

A mixture of N-(3-ethylphenyl)-N-methylcyanamide (520 mg, 3.3 mmol), 2,5-dichloroaniline hydrochloride (600 mg, 3 mmol), and chlorobenzene (2 mL) were combined in a dry round bottom flask equipped with a water cooled condenser under nitrogen and placed in a preheated oil bath (150-160°C). The reaction mixture was heated for 4 hours. After cooling, the crude reaction product was purified by crystallization from chlorobenzene/diethylether. The resulting crystals were collected by filtration, washed with diethylether, and dried in a vacuum oven (40°C, 15 hours) to yield the title compound, N-(3-ethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine hydrochloride, as a white solid (760 mg, 72% yield).

TLC: R_f = 0.45 (10% MeOH/CH₂Cl₂); mp: 162-163°C; ¹H NMR (CD₃OD): δ 7.53-7.23 (m, 7H, Ar-H), 3.48 (s, 3H, CH₃), 2.70 (q, J = 7.6 Hz, 2H, CH₂), 1.26 (t, J = 7.6 Hz, 3H, CH₃); MS(EI): m/e 322 (M⁺ for the free base); Anal.: C₁₆H₁₇Cl₂N₃•HCl; Calcd. (%): C: 53.57, H: 5.05, N: 11.71; Found (%): C: 53.66, H: 5.20, N: 11.71.

EXAMPLE 2 - Preparation of N-(3-ethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = CH₃, R₂ = H, R₃ = R₄ = Br, n = 0).

Part 1: Preparation of 2,5-dibromoaniline hydrochloride

To a solution of 2,5-dibromoaniline (Aldrich, 1.5 g, 6 mmol) in methanol (5 mL) was added methanolic HCl (1M, 30 mL) at 4°C, then the reaction mixture was stirred at 25°C for 30 minutes. The reaction mixture became a light brown solution with a white precipitate. The precipitate was collected by filtration, washed with diethylether (2 mL), and dried under vacuum to afford 1.6 g of 2,5-dibromoaniline hydrochloride (93% yield).

Part 2: Guanidine Synthesis

A mixture of N-(3-ethylphenyl)-N-methylcyanamide (520 mg, 3.3 mmol), 2,5-dibromoaniline hydrochloride (861 mg, 3 mmol), and chlorobenzene (2 mL) were combined in a dry round bottom flask equipped with water cooled condenser under nitrogen and placed in a preheated oil bath (150-160°C). The reaction mixture was heated for 3 hours. After cooling, the crude reaction product was purified by crystallization from chlorobenzene/diethylether. The resulting crystals were collected by filtration, washed with diethylether, and dried in a vacuum oven (40°C, 15 hours) to yield the title compound, N-(3-ethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride, as a white solid (780 mg, 59% yield).

TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); mp: 217-218°C; ¹H NMR (CD₃OD): δ 7.56-7.20 (m, 7H, Ar-H), 3.41 (s, 3H, CH₃), 2.62 (q, J = 7.7Hz, 2H, CH₂), 1.18 (t, J = 7.7Hz, 3H, CH₃); MS(EI): m/e 411 (M⁺ for the free base); Anal.: C₁₆H₁₇Br₂N₃•HCl; Calcd. (%): C: 42.93, H: 4.05, N: 9.39; Found (%): C: 42.90, H: 4.01, N: 9.13.

EXAMPLE 3 - Preparation of N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)guanidine mesylate (Formula I: mesylate of R = 3-ethylphenyl, $R^1 = R^2 = H$, $R^3 = R^4 = Cl$, $n = 0$).

5 **Part 1: Preparation of 2,5-dichlorophenylcyanamide**

To a heterogeneous slurry of 2,5-dichloroaniline (3.0 g, 18.5 mmol) in 60 mL of water at 4°C was added solid BrCN (1.22 g, 11.3 mmol) slowly. After 5 minutes the cooling bath was removed and the heterogeneous reaction mixture was stirred at room temperature for 24
10 hours to yield the product in water suspension. The product was collected by filtration, washed with water (100 mL), and dried under vacuum to yield the pure product (2 g, 60% yield).

Part 2: Preparation of 3-ethylaniline mesylate

15 To a solution of 3-ethylaniline (Aldrich, 4.84 g, 40 mmol) in methanol (10 mL) was added methanesulfonic acid (4.4 g, 45 mmol) at 4°C, then the reaction mixture was stirred at 25°C for 30 minutes to yield a solution with white precipitates. The precipitates were collected by filtration, washed with ether, and dried under vacuum to afford 7.7 g
20 of 3-ethylaniline mesylate (7.7 g, 91% yield).

Part 3: Guanidine Synthesis

A mixture of 2,5-dichlorophenylcyanamide (1.02 g, 5.5 mmol), 3-ethylaniline mesylate (1.1 g, 5 mmol), and chlorobenzene (15 mL) were
25 combined in a dry round bottom flask equipped with a water cooled condenser under nitrogen and placed in a preheated oil bath (150-160°C). The reaction mixture was heated for 2 hours. After cooling, the crude reaction product was purified by crystallization from

chlorobenzene/diethylether. The resulting crystals were collected by filtration, washed with diethylether, and dried in a vacuum oven (40°C, 15 hours) to yield the title compound, N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)guanidine mesylate, as a white solid (1.5 g, 75% yield).

5 TLC: R_f = 0.4 (10% MeOH/CH₂Cl₂); mp: 220-221°C; ¹H NMR (300 MHz, CD₃OD): δ 7.58-7.17 (m, 7H, Ar-H), 2.68 (s, 3H, SO₃CH₃), 2.68 (m, 2H, CH₃), 1.24 (t, J = 7.6 Hz, CH₃); Anal: C₁₆H₁₉Cl₂N₃O₃; Calcd. (%): C: 47.83, H: 4.74, N: 10.39; Found (%): C: 47.44, H: 4.64, N: 10.27.

10

EXAMPLE 4 - Preparation of N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine mesylate (Formula I: mesylate of R = 3-ethylphenyl, R¹ = R² = H, R³ = Cl, R⁴ = CH₂CH₃, n = 0).

15 Part 1: Preparation of 2-chloro-5-ethylphenylcyanamide

To a heterogeneous slurry of 2-chloro-5-ethylaniline (1.6 g, 10 mmol) in 60 mL of water at 4°C was added solid BrCN (0.848 g, 8 mmol) slowly. After 5 minutes the cooling bath was removed and the heterogeneous reaction mixture was stirred at room temperature for 24
20 hours to yield the product in water suspension. The precipitates were collected by filtration, washed with water (100 mL), and dried under vacuum to yield the pure title compound (1.45 g, 80% yield).

Part 2: Guanidine Synthesis

25 A mixture of 2-chloro-5-ethylphenylcyanamide (0.6 g, 3.08 mmol), 3-ethylaniline mesylate (0.64 g, 2.93 mmol), and chlorobenzene (12 mL) were combined in a dry round bottom flask equipped with a water cooled condenser under nitrogen and placed in a preheated oil

bath (150-160°C). The reaction mixture was heated for 3 hours. After cooling, the crude reaction product was purified by crystallization from chlorobenzene/diethylether. The resulting crystals were collected by filtration, washed with diethylether, and dried in a vacuum oven (40°C, 15 hours) to yield the title compound, N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine mesylate, as a white solid (1.1 g, 91% yield).

TLC: R_f = 0.4 (10% MeOH/CH₂Cl₂); mp: 162-163°C; ¹H NMR (300 MHz, CD₃OD): δ 7.48-7.17 (m, 7H, Ar-H), 2.69 (s, 3H, SO₃CH₃), 2.67 (q, J = 7.6 Hz, 4H, (H₂)), 1.24 (t, J = 7.5 Hz, 6H, CH₃); Anal.: C₁₈H₂₄ClN₃SO₃; Calcd. (%): C: 54.33, H: 6.08, N: 10.56; Found (%): C: 53.98, H: 6.14, N: 10.40.

EXAMPLE 5

Other substituted aniline intermediates, suitable for reaction with an appropriate cyanamide compound to provide compounds of the invention as described above, are either commercially available or can be prepared by methods generally known to those skilled in the synthesis art. The following Examples 5a through 5d disclose procedures for preparation of four different substituted aniline compounds that are suitably used to prepare compounds of the invention, including e.g. the compounds of Examples 23, 58, 64, 69 and 70 which follow.

Example 5a - Preparation of 2-Bromo-5-methylthioaniline hydrochloride

To a stirred solution (cooled to 16-19°C) of 2-bromo-5-(methylthio)benzoic acid (1.5 g, 6.07 mmol, prepared by the method described in Kuenzle, F., et al., *Helv. Chim. Acta.*, 52(3):622-628 (1969)) in DMF (17 mL) was added triethylamine (1.05 mL, 7.28 mmol).

After stirring briefly, diphenylphosphoryl azide (1.7 mL, 7.59 mmol) was added by an addition funnel over a 15 minute period. After 2 hours of stirring at ambient temperature, thin layer chromatography (SiO₂, cyclohexane/ethyl acetate 8:1) showed the reaction was completed. To this solution was added distilled water (7 mL) and the mixture was then heated to 65°C for 2 hours.

The reaction mixture was concentrated in vacuo at 45°C to afford a light yellow, syrupy residue. After adding water (50 mL) to this residue, saturated potassium carbonate was added until pH 9. The mixture was then extracted with 40 mL of methylene chloride two times. The combined extracts were washed with brine, dried over MgSO₄ and concentrated in vacuo to yield a yellow oil. The yellow oil was dissolved in 10 mL of ether and added HCl/ether (10 mL, 1N) to provide a white precipitate. The solid was collected by filtration and further purified by column chromatography (SiO₂, hexanes/EtOAc: 100%-80%). The final product was a white solid (0.6 g, 39% in yield); ¹H NMR (CD₃OD): δ (ppm) 7.76 (d, 1H, 8.5 Hz), 7.20 (s, 1H), 7.18 (d, 1H), 2.50 (s, 3H, CH₃); Anal: C₇H₈BrNS•HCl; Calcd. (%): C: 33.03, H: 3.56, N: 5.50; Found (%): C: 33.00, N: 3.52, N: 5.59.

Example 5b - Preparation of N-Methyl-3-methylsulfinylaniline hydrochloride

Part 1: N-Methyl-(3-methylthiophenyl)amine: 3-Methylmercaptoaniline (5 g, 34.8 mmol) was dissolved in formic acid (1.92 mL, 49 mmol) and heated to 100-105°C under argon for overnight. The reaction mixture was cooled to room temperature and extracted with CH₂Cl₂ (75 ml). The organic layer was washed with saturated Na₂CO₃ (30 ml) three

times and dried over MgSO_4 , filtered to remove MgSO_4 and the solution concentrated to afford the formamide. The formamide was dissolved in anhydrous THF (30 ml) under argon. To this solution was added slowly LiAlH_4 in THF (50 ml, 1 M) at 0-5°C. The reaction was warmed up to
5 room temperature and stirred for 20 hours. To this reaction mixture was added 50 ml of saturated aqueous MgSO_4 . The organic layer was saved. The water layer was further extracted with ethyl acetate (50 ml) three times and the combined organic solution was washed with H_2O (50 ml), brine (50 ml) and dried over MgSO_4 . The solution was filtered
10 to remove MgSO_4 and then concentrated to yield the crude product which was purified by column chromatography (SiO_2 , hexanes/ EtOAc : 8/1). The fractions which contained the product were collected and concentrated, dried under vacuum to yield the pure N-Methyl-(3-methylthiophenyl)amine (5.25 g, 98% in yield).

15

Part 2: N-Methyl-3-methylsulfinylaniline hydrochloride

Hydrogen peroxide (30% in water, 10.22 mL, 1 mol, Aldrich) was added to a solution of N-methyl-3-methylmercaptoaniline (3.0 g, 19.6 mmol) in acetone (17 mL) at 0-5°C. The reaction was stirred overnight
20 and then the acetone was removed. A 1N NaOH aqueous solution was added until pH 12, which was then extracted with ether (30 ml) three times. The combined organic layers were dried over MgSO_4 , and then the solution was filtered to remove MgSO_4 and the resulting solution concentrated to yield the crude product of the title compound which
25 was purified by column chromatography (silica gel, eluted by EtOAc/MeOH : 100%-90%). N-Methyl-3-methylsulfinylaniline was obtained and was further converted to its hydrochloride salt (1.82 g, 45% in yield).

^1H NMR (CD_3OD): δ (ppm) 7.90-7.55 (m, Ar-H, 4H), 3.11 (s, NCH_3 , 3H), 2.85 (s, SOCH_3 , 3H); MS(EI): m/e 169 (M^+ for the free base); TLC: R_f = 0.29 (SiO_2 , EtOAc); M.P.: 137-138°C.

5 Example 5c - Preparation of N-Methyl-3-methylsulfonyl aniline hydrochloride

Hydrogen peroxide (30% in water, 10.22 mL, 1 mol, Aldrich) was added to a solution of N-methyl-3-methylmercaptoaniline (3.0 g, 19.6 mmol) in acetone (17 mL) at 0-5°C. The reaction was stirred for
10 overnight and then the acetone was removed. A 1N NaOH aqueous solution was added until pH 12, which solution was then extracted with 30 ml of ethyl ether three times and the combined organic layers were dried MgSO_4 . The MgSO_4 was removed by filtration and the resulting solution was concentrated to yield the crude product which was purified
15 by column chromatography (silica gel, eluted by EtOAc/MeOH 100%-90%). N-methyl-3-methylsulfonyl aniline was obtained and further converted to its hydrochloride salt (1.8 g, 42% in yield).

^1H NMR (CD_3OD): δ (ppm) 7.90-7.50 (m, Ar-H, 4H), 3.16 (s, SO_2CH_3 , 3H), 3.05 (s, NCH_3 , 3H); MS(EI): m/e 185 (M^+ : $\text{C}_8\text{H}_{11}\text{NSO}_2$);
20 TLC: R_f = 0.81 (SiO_2 , EtOAc); M.P.: 169-170°C.

Example 5d - Preparation of 2-Fluoro-5-ethylaniline

Part 1: 3-Nitro-4'-fluoroacetophenone: To stirred, pre-cooled fuming nitric acid (40 mL) at -10°C was added dropwise 4'-fluoroacetophenone
25 (Aldrich, 75 g, 54.3 mmol) over a period of 10 minutes. The temperature was strictly maintained at -9 to -10°C for a total of 8 hours. The reaction mixture flask was then transferred to the freezer (-10°C) for storage overnight. In the morning the reaction mixture was

poured onto ice (1.5 Kg). The resultant mixture was extracted three times with ether (400 mL). The organic layer was washed four times with NaOH (1N, 300 mL) and brine. Concentration in vacuo afforded a yellow liquid which by thin layer chromatography (SiO₂,

5 cyclohexane/ethyl acetate: 2/1) showed one major and two minor products. The crude product was purified over 600 grams of 230-400 mesh silica gel, eluting with a gradient of hexanes-ethyl acetate 10:1 to 3:1. The product containing fractions were concentrated to afford a light yellow liquid (27.6 grams).

10

Part 2: 3'-Amino-4'-fluoroacetophenone: To a stirred mixture of 3'-nitro-4'-fluoroacetophenone (10.04 g, 55 mmol) in 72 mL of concentrated hydrochloric acid, was added tin (II) chloride dihydrate (37 grams), in portions. After approximately one third of the material had been added, 15 a rapid rise in the internal reaction temperature (to 95°C) was noted. The mixture was then heated to reflux for 10 minutes, this resulted in the dissolution of all solids to give a solution. The mixture was then cooled to room temperature and poured onto an ice/water mixture (150 g). The mixture was then further cooled in an ice bath while 50% 20 sodium hydroxide was added until pH 12 was reached. The aqueous layer was extracted twice with ether (50 mL). The combined organic extracts were washed with brine and then dried over sodium sulfate. Removal of the drying agent and in vacuo concentration of the filtrate afforded a yellow-orange oil (8.73 g) which was recrystallized on 25 standing. This material was of sufficient purity to be used directly in the next step (Part 3).

Part 3: 2-Fluoro-5-ethylaniline: To a stirred mixture of 3'-amino-4'-fluoroacetophenone (7.56 g, 49.4 mmol) in triethylene glycol (60 mL) was added 4.94 g of sodium hydroxide. Neat hydrazine hydrate (7.2 mL) was added to the mixture in one portion via a syringe. This addition
5 resulted in a slight exotherm (temperature around 50°). The reaction flask (three neck, equipped with claisen adapter and receiving flask) was then equipped with a heating mantle and the reaction heated to 100°C for 1 hour, then 150°C. At the higher temperature distillate began to collect in the receiving flask. After 1 hour at 150°C the reaction
10 mixture was then heated to 180°C, while still collecting distillate. After 45 minutes at 180°C thin layer chromatography indicated the complete absence of starting material and the appearance of a single major product. The reaction mixture was cooled to room temperature with an ice bath and poured into 100 mL of water. The aqueous mixture was
15 extracted three times with ether (125 mL). The combined organic extracts were washed once with water, once with brine and then dried over potassium carbonate. Concentration of the organic extracts in vacuo afforded 2-fluoro-5-ethylaniline (6.82 g) as an amber liquid. This material was further purified by column chromatography (silica gel,
20 hexanes/ethyl acetate: 2/1) to give 7.11 grams of product as a viscous liquid.

¹H NMR (CDCl₃): δ (ppm) 8.0-7.0 (m, Ar-H), 2.52 (q, CH₂), 1.20 (t, CH₃); MW: 139.18 (for the free base); Anal.: C₈H₁₀NF; Calcd. (%): C: 69.04, H: 7.24, N: 10.07; Found (%): C: 69.03; N: 7.49, N: 9.89.

25

EXAMPLES 6-73

By procedures similar to those employed in Examples 1 through 5 above but using appropriately substituted amine hydrochloride and

cyanamide reagents, the following compounds of Formulas I and II were prepared having the specified physical characteristics.

Example 6 - N-(3-Ethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)-

- 5 N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, $R^1 = R^2 = \text{CH}_3$, $R_3 = R_4 = \text{Cl}$, $n = 0$).

white solid; TLC: $R_f = 0.4$ (10% MeOH/ CH_2Cl_2); mp: 161-162°C;

^1H NMR (300 MHz, CD_3OD): δ 7.38-7.09 (m, 7H, Ar-H), 3.44 (s, 3H, CH_3), 3.38 (s, 3H, CH_3), 2.51 (q, $J = 7.6\text{Hz}$, 2H, CH_2), 1.16 (t,

- 10 $J = 7.6\text{Hz}$, 3H, CH_3); Anal.: ($\text{C}_{17}\text{H}_{19}\text{Cl}_2\text{N}_3 \cdot \text{HCl} \cdot \text{H}_2\text{O}$); Calcd. (%): C: 52.26, H: 5.68, N: 10.75; Found (%): C: 51.94, H: 5.59, N: 10.44.

Example 7 - N-(3-Ethylphenyl)-N'-(2,5-dichlorophenyl)-N'-

- 15 methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = R^4 = \text{Cl}$, $n = 0$).

white solid; TLC: $R_f = 0.4$ (10% MeOH/ CH_2Cl_2); mp = 92-93°C, ^1H

NMR (300 MHz, CD_3OD): δ 7.76-7.12 (m, 7H, Ar-H), 3.44 (s, 3H, CH_3), 2.68 (q, $J = 7.6\text{Hz}$, 2H, CH_2), 1.24 (t, $J = 7.6\text{Hz}$, 3H, CH_3); Anal.: ($\text{C}_{16}\text{H}_{17}\text{Cl}_2\text{N}_3 \cdot \text{HCl}$), Calcd. (%) C: 53.58, H: 5.06, N: 11.91; Found (%):

- 20 C: 53.49, H: 5.20, N: 11.92; MS (EI) = m/e 321 (M^+ for the free base).

Example 8 - N-(3-Ethylphenyl)-N'-(2,5-dichlorophenyl)guanidine

hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl,

$R^1 = R^2 = \text{H}$, $R^3 = R^4 = \text{Cl}$, $n = 0$).

- 25 white solid; TLC: $R_f = 0.4$ (10% MeOH/ CH_2Cl_2); mp: 111-112°C;

^1H NMR (300 MHz, CD_3OD): δ 7.58-7.15 (m, 7H, Ar-H), 2.68 (q, $J = 7.6\text{Hz}$, 2H, CH_2), 1.24 (t, $J = 7.6\text{Hz}$, 3H, CH_3); MS (EI): m/e 308 (M^+

for the free base); Anal.: (C₁₅H₁₅Cl₂N₃•HCl); Calcd. (%): C: 52.27, H: 4.68, N: 12.19; Found (%): C: 52.17, H: 4.76, N: 12.25.

Example 9 - N-(3-Ethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)-
5 N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = R² = CH₃, R³ = R⁴ = Br, n = 0).

white solid; TLC: R_f = 0.3 (10% MeOH/CH₂Cl₂); mp: 179-180°C;
1H NMR (300 MHz, CD₃OD): δ 7.48-7.10 (m, 7H, Ar-H), 3.45 (s, 3H, CH₃), 3.38 (s, 3H, CH₃), 2.52 (q, J = 7.7 Hz, 2H, CH₂), 1.18 (t,
10 J = 7.7 Hz, 3H, CH₃); MS (EI): m/e 425 (M⁺ for the free base); Anal.: (C₁₇H₁₉Br₂N₃•HCl); Calcd. (%): C: 44.23, H: 4.37, N: 9.10; Found (%): C: 44.00, H: 4.57, N: 9.04.

Example 10 - N-(3-Ethylphenyl)-N'-(2,5-dibromophenyl)guanidine
15 hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = R² = H, R³ = R⁴ = Br, n = 0).
white solid; TLC: R_f = 0.54 (10% MeOH/CH₂Cl₂); mp: 76-77°C;
1H NMR (300 MHz, CD₃OD): δ 7.70-7.15 (m, 7H, Ar-H), 2.67 (q,
J = 7.6 Hz, 2H, CH₂), 1.24 (t, J = 7.6 Hz, 3H, CH₃); MS (EI): m/e 397 (M⁺
20 for the free base); HRMS: 394.9618 (394.9632 calculated for C₁₅H₁₅Br₂N₃).

Example 11 - N-(3-Ethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride
25 salt of R = 3-ethylphenyl, R¹ = CH₃, R² = H, R³ = Cl, R⁴ = CF₃, n = 0).
white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); mp: 180-181°C;
1H NMR: δ 7.76-7.25 (m, 7H, Ar-H), 3.53 (s, 3H, CH₃), 2.70 (q,
J = 7.5 Hz, 2H, CH₂), 1.26 (t, J = 7.5 Hz, 3H, CH₃); MS (EI): m/e 355

(M⁺ for the free base); Anal.: (C₁₇H₁₇ClF₃N₃•HCl); Calcd. (%): C: 52.05, H: 4.63, N: 10.71; Found (%): C: 52.15, H: 4.53, N: 10.72.

Example 12 - N-(3-Ethylphenyl)-N'-(2-chloro-5-

5 trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = R² = H, R³ = Cl, R⁴ = CF₃, n = 0).

white solid; TLC: R_f = 0.4 (10% MeOH/CH₂Cl₂); mp: 73-74°C;

¹H NMR: δ 7.55-7.16 (m, 7H, Ar-H), 2.60 (q, J = 7.6Hz, 2H, CH₂), 1.21 (t, J = 7.6Hz, 3H, CH₃); MS (EI): m/e 341 (M⁺ for the free base); HRMS:

10 341.0907 (341.0917 calculated for C₁₆H₁₅ClF₃N₃).

Example 13 - N-(3-Ethylphenyl)-N-methyl-N'-(2-bromo-5-

trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = CH₃, R² = H, R³ = Br, R⁴ = CF₃, n = 0).

15 white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); mp: 184-185°C;

¹H NMR: δ 7.93-7.28 (m, 7H, Ar-H), 3.50 (s, 3H, CH₃), 2.70 (q, J = 7.6Hz, 2H, CH₂), 1.25 (t, J = 7.6Hz, 3H, CH₃); MS (EI): m/e 400 (M⁺ for the free base); Anal.: (C₁₇H₁₇BrF₃N₃•HCl); Calcd. (%): C: 46.76, H: 4.15, N: 9.62; Found (%): C: 46.57, H: 4.12, N: 9.36.

20

Example 14 - N-(3-Ethylphenyl)-N'-(2-bromo-5-

trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = R² = H, R³ = Br, R⁴ = CF₃, n = 0).

white solid; TLC: R_f = 0.4 (10% MeOH/CH₂Cl₂); mp: 109-110°C;

25 ¹H NMR: δ 7.77-7.17 (m, 7H, Ar-H), 2.61 (q, J = 7.7Hz, 2H, CH₂); MS(EI): m/e 386 (M⁺ for the free base); HRMS: 385.0391 (385.0401 calculated for C₁₆H₁₅BrF₃N₃).

Example 15 - N-(3-Ethylphenyl)-N-methyl-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=CH₃, R²=H, R³=F, R⁴=CF₃, n=0).

white solid; TLC: R_f=0.5 (10% MeOH/CH₂Cl₂); mp: 158-159°C;

5 ¹H NMR: δ 8.20-7.20 (m, 7H, Ar-H), 3.43 (s, 3H, CH₃), 2.61 (q, J=7.6Hz, 2H, CH₂), 1.17 (t, J=7.6Hz, 3H, CH₃); MS (EI): m/e 339 (M⁺ for the free base); Anal.: (C₁₇H₁₇F₄N₃•HCl); Calcd. (%): C: 54.33, H: 4.83, N: 11.18; Found (%): C: 54.20, H: 4.90, N: 11.04.

10 Example 16 - N-(3-Ethylphenyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=F, R⁴=CF₃, n=0).

white solid; TLC: R_f=0.4 (10% MeOH/CH₂Cl₂); mp: 105-106°C;

¹H NMR: δ 7.25-6.85 (m, 7H, Ar-H), 2.60 (q, J=7.7Hz, 2H, CH₂), 1.21 (t, J=7.6Hz, 3H, CH₃); MS (EI): m/e 325 (M⁺ for the free base); HRMS: 325.1212 (325.1202 calculated for C₁₆H₁₅N₃F₄).

Example 17 - N-(3-Ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=CH₃, R³=Cl, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.3 (10% MeOH/CH₂Cl₂); mp: 129-130°C;

¹H NMR (300 MHz, CD₃OD): δ 7.28-7.01 (m, 7H, Ar-H), 3.42 (s, 3H, CH₃), 3.39 (s, 3H, CH₃), 2.49 (q, J=7.6Hz, 2H, CH₂), 2.34 (q, J=7.6Hz, 2H, CH₂), 1.13 (t, J=7.7Hz, 3H, CH₃), 1.05 (t, J=7.7Hz, 3H, CH₃); MS (EI): m/e 330 (M⁺ for the free base).

Example 18 - N-(3-Ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=CH₃, R²=H, R³=Cl, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.4 (10% MeOH/CH₂Cl₂); mp: 190-191 °C;

5 ¹H NMR (300 MHz, CD₃OD): δ 7.44-7.20 (m, 7H, Ar-H), 3.48 (s, 3H, CH₃), 2.71 (q, J=7.6Hz, 2H, CH₂), 2.65 (J=7.6Hz, 2H, CH₂), 1.27 (t, J=7.7Hz, 3H, CH₃), 1.23 (t, J=7.7Hz, 3H, CH₃); MS (EI): m/e 315 (M⁺ for the free base); Anal.: (C₁₈H₂₂ClN₃•HCl); Calcd. (%): C: 61.36, H: 6.58, N: 11.93; Found (%): C: 61.09, H: 6.37, N: 11.86.

10

Example 19 - N-(3-Ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=Cl, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.5 (10% MeOH/CH₂Cl₂); mp: 77-78 °C;

15 ¹H NMR (300 MHz, CD₃OD): δ 7.49-7.18 (m, 7H, Ar-H), 2.69 (q, J=7.6Hz, 4H, CH₂), 1.24 (t, J=7.6Hz, 6H, CH₃); MS (EI): m/e 301 (M⁺ for the free base); Anal.: (C₁₇H₂₀ClN₃•HCl); Calcd. (%): C: 60.36, H: 6.26, N: 12.42; Found (%): C: 60.33, H: 6.42, N: 12.37.

20

Example 20 - N-(3-Ethylphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=CH₃, R²=H, R³=Br, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.4 (10% MeOH/CH₂Cl₂); mp: 189-190 °C;

25 ¹H NMR (300 MHz, CD₃OD): δ 7.62-7.18 (m, 7H, Ar-H), 3.49 (s, 3H, CH₃), 2.71 (q, J=7.6Hz, 2H, CH₂), 2.64 (q, J=7.6Hz, 2H, CH₂), 1.26 (t, J=7.6Hz, 3H, CH₃), 1.23 (t, J=7.7Hz, 3H, CH₃); MS (EI): m/e 360 (M⁺ for the free base); Anal.: (C₁₈H₂₂BrN₃•HCl); Calcd. (%): C: 54.49, H: 5.84, N: 10.59; Found (%): C: 54.46, H: 5.95, N: 10.62.

Example 21 - N-(3-Ethylphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=Br, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.54 (10% MeOH/CH₂Cl₂); mp: 70-71 °C;

5 ¹H NMR (300 MHz, CD₃OD): δ 7.62-7.10 (m, 7H, Ar-H), 2.71-2.62 (m, 4H, CH₂), 1.27 (t, J=7.6Hz, 3H, CH₃), 1.22 (t, J=7.7Hz, 3H, CH₃);
Anal.: (C₁₇H₂₀BrN₃•HCl); Calcd. (%): C: 53.35, H: 5.53, N: 10.98;
Found (%): C: 53.61, H: 5.56, N: 11.04; MS(EI): m/e 345 (M⁺ for the free base).

10

Example 22 - N-(3-Ethylphenyl)-N-methyl-N'-(2-fluoro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=CH₃, R²=H, R³=F, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.4 (10% MeOH/CH₂Cl₂); mp: 171-172 °C;

15 ¹H NMR (300 MHz, CD₃OD): δ 7.45-7.14 (m, 7H, Ar-H), 3.48 (s, 3H, CH₃), 2.70 (q, J=7.6Hz, 2H, CH₂), 2.64 (q, J=7.5Hz, 2H, CH₂), 1.26 (t, J=7.7Hz, 3H, CH₃), 1.22 (t, J=7.5Hz, 3H, CH₃); MS (EI): m/e 299 (M⁺ for the free base); Anal.: (C₁₈H₂₂FN₃•HCl); Calcd. (%): C: 64.37, H: 6.90, N: 12.51; Found (%): C: 64.49, N: 7.01, N: 12.45.

20

Example 23 - N-(3-Ethylphenyl)-N'-(2-fluoro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=F, R⁴=CH₂CH₃, n=0).

white solid; TLC: R_f=0.3 (10% MeOH/CH₂Cl₂); mp=52.53 °C;

25 ¹H NMR (300 MHz, CD₃OD): δ 7.34-7.11 (m, 7H, Ar-H), 2.70-2.61 (m, 4H, CH₂), 1.26-1.20 (m, 6H, CH₃); Anal.: (C₁₇H₂₀FN₃•HCl); Calcd. (%): C: 63.45, H: 6.58, N: 13.06; Found (%): C: 63.52, H: 6.77, N: 13.32; MS(EI): m/e 285 (M⁺ for the free base).

Example 24 - N-(3-Ethylphenyl)-N-methyl-N'-(2-chloro-5-methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = CH₃, R² = H, R³ = Cl, R⁴ = CH₃, n = 0):

white solid; TLC: R_f = 0.45 (10% MeOH/CH₂Cl₂); mp: 204-205°C;

- 5 ¹H NMR (300 MHz, CD₃OD): δ 7.46-7.16 (m, 7H, Ar-H), 3.48 (s, 3H, CH₃), 2.70 (q, J = 7.6Hz, 2H, CH₂), 2.33 (s, 3H, CH₃), 1.26 (t, J = 7.6Hz, 3H, CH₃); MS (EI): m/e 302 (M⁺ for the free base); Anal.: (C₁₇H₂₀ClN₃•HCl); Calcd. (%): C: 60.36, H: 6.26, N: 12.42; Found (%): C: 60.23, H: 6.50, N: 12.32.

10

Example 25 - N-(3-Ethylphenyl)-N'-(2-chloro-5-methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = R² = H, R³ = Cl, R⁴ = CH₃, n = 0):

white solid; TLC: R_f = 0.35 (10% MeOH/CH₂Cl₂); mp: 88-89°C;

- 15 ¹H NMR (300 MHz, CD₃OD): δ 7.45-7.18 (m, 7H, Ar-H), 2.69 (q, J = 7.7Hz, 2H, CH₂), 2.37 (s, 3H, CH₃), 1.25 (t, J = 7.7Hz, 3H, CH₃); MS (EI): m/e 288 (M⁺ for the free base); Anal.: (C₁₆H₁₈ClN₃•HCl•0.5H₂O); Calcd. (%): C: 57.66, H: 6.05, N: 12.61; Found (%): C: 57.36, H: 6.08, N: 12.46.

20

Example 26 - N-(3-Ethylphenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, R¹ = CH₃, R² = H, R³ = Cl, R⁴ = SCH₃, n = 0):

white solid; TLC: R_f = 0.45 (10% MeOH/CH₂Cl₂); mp: 198-199°C;

- 25 MS (EI): m/e 333 (M⁺ for the free base); ¹H NMR (CD₃OD): δ 7.45-7.20 (m, 7H, Ar-H), 3.49 (s, 3H, CH₃), 2.70 (q, J = 7.5Hz, 2H, CH₂), 2.49 (s, 3H, SCH₃), 1.26 (t, J = 7.5Hz, 3H, CH₃); Anal.: (C₁₇H₂₀ClN₃S•HCl);

Calcd. (%): C: 55.14, H: 5.72, N: 11.35; Found (%): C: 54.99, H: 5.63, N: 11.23.

Example 27 - N-(3-Ethylphenyl)-N'-(2-chloro-5-

- 5 methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=Cl, R⁴=SCH₃, n=0).
white solid; TLC: R_f = 0.45 (10% MeOH/CH₂Cl₂); mp = 132-133°C; ¹H NMR (CD₃OD): δ 7.50-7.18 (m, 7H, Ar-H), 2.69 (q, J=7.6Hz, 2H, CH₂), 2.51 (s, 3H, CH₃), 1.25 (t, J=7.6Hz, 3H, CH₃);
10 Anal.: (C₁₆H₁₈ClN₃S•HCl); Calcd. (%): C: 53.93, N: 11.79, H: 5.37; Found (%): C: 54.09, N: 11.72, H: 5.44.

Example 28 - N-(1-Naphthyl)-N'-(2-fluoro-5-

- 15 methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=1-naphthyl, R¹=R²=H, R³=F, R⁴=CH₃, n=0).
white solid; mp 194°C; ¹H NMR (300 MHz, CD₃OD): δ 7.98-8.15 (m, 2, Ar-H), 7.57-7.68 (m, 3, Ar-H) 7.15-7.24 (d, 5, Ar-H); 2.35 (s, 3, CH₃); MS (EI); m/e 293 (M⁺ for free base).

20 Example 29 - N-(1-Naphthyl)-N'-(2,5-dichlorophenyl)-N'-

- methylguanidine hydrochloride (Formula I: hydrochloride salt of R=1-naphthyl, R¹=H, R²=CH₃, R³=R⁴=Cl, n=0).
white solid; mp 210°C, ¹H NMR (300 MHz, CD₃OD): δ 7.96-8.02 (m, 3, Ar-H), 7.48-7.64 (m, 7, Ar-H); 3.52 (s, 3, N-CH₃); MS (EI):
25 m/e 344 (M⁺ for free base); Anal.: (C₁₈H₁₅Cl₂N₃•HCl•0.25 H₂O); Calcd. (%): C: 56.13, H: 4.32, N: 10.91; Found (%): C: 56.02, H: 4.60, N: 10.73.

Example 30 - N-(1-Naphthyl)-N'-(2-chloro-5-methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $R^1 = R^2 = H$, $R^3 = Cl$, $R^4 = CH_3$, $n = 0$).

white solid; mp 125°C; 1H NMR (300 MHz, CD_3OD): δ 7.95-8.10 (m, 3, Ar-H), 7.52-7.70 (m, 6, Ar-H); 7.41-7.48 (d, 1, Ar-H); 7.30-7.35 (s, 1, Ar-H); 7.20-7.25 (m, 2, Ar-H); 2.37 (s, 3, Ar- CH_3); MS (EI): m/e 310 (M^+ for free base); Anal.: ($C_{18}H_{16}ClN_3 \cdot HCl$); Calcd. (%): C: 62.44, H: 4.95, N: 12.14; Found (%): C: 62.52, H: 5.04, N: 11.96.

Example 31 - N-(1-Naphthyl)-N'-(2,5-dimethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $R^1 = R^2 = H$, $R^3 = R^4 = CH_3$, $n = 0$).

white solid; mp 122-123°C; 1H NMR (300 MHz, CD_3OD): δ 7.95-8.08 (m, 3, Ar-H), 7.55-7.71 (m, 4, Ar-H); 7.10-7.28 (m, 3, Ar-H); 2.32 (s, 6, 2 Ar- CH_3); MS (EI): m/e 289 (M^+ for free base); Anal.: ($C_{19}H_{19}N_3 \cdot HCl$); Calcd. (%): C: 70.04, H: 6.19, N: 12.90; Found (%): C: 70.02, H: 6.20, N: 12.87.

Example 32 - N-(1-Naphthyl)-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $R^1 = R^2 = H$, $R^3 = R^4 = Br$, $n = 0$).

white solid; mp 231-232°C; 1H NMR (300 MHz, CD_3OD): δ 7.97-8.13 (m, 3, Ar-H), 7.48-7.72 (m, 7, Ar-H); MS (EI): M/e 419 (M^+ for free base).

25

Example 33 - N-(1-Naphthyl)-N'-(2-chloro-5-methylphenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $R^1 = H$, $R^2 = CH_3$, $R^3 = Cl$, $R^4 = CH_3$, $n = 0$).

white solid; mp 228-229°C; ^1H NMR (300 MHz, CD_3OD): δ 7.96-7.99 (m, 3, Ar-H), 7.48-7.61 (m, 6, Ar-H); 7.26-7.30 (d, 1, Ar-H); 3.50 (s, 3, N- CH_3); 2.39 (s, 3, Ar- CH_3) MS (EI): m/e 324 (M^+ for free base); Anal.: ($\text{C}_{19}\text{H}_{18}\text{ClN}_3\cdot\text{HCl}$); Calcd. (%): C: 63.34, H: 5.32, N: 11.66; Found (%): C: 63.20, H: 5.43, N: 11.66.

Example 34 - N-(1-Naphthyl)-N'-(2,5-dimethylphenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $\text{R}^1 = \text{H}$, $\text{R}^2 = \text{CH}_3$, $\text{R}^3 = \text{R}^4 = \text{CH}_3$, $n = 0$).

white solid; mp 216-217°C; ^1H NMR (300 MHz, CD_3OD): δ 7.95-8.00 (m, 2, Ar-H), 7.5-7.7 (m, 4, Ar-H); 7.18-7.38 (m, 4, Ar-H); 3.5 (br s, 3, N- CH_3); 2.38 (s, 3, Ar- CH_3); MS (EI): m/e 303 (M^+ for free base); Anal.: ($\text{C}_{20}\text{H}_{21}\text{N}_3\cdot\text{HCl}$); Calcd. (%): C: 70.68, H: 6.52, N: 12.36; Found (%): C: 70.51, H: 6.46, N: 12.18.

Example 35 - N-(1-Naphthyl)-N'-(2,5-dibromophenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $\text{R}^1 = \text{H}$, $\text{R}^2 = \text{CH}_3$, $\text{R}^3 = \text{R}^4 = \text{Br}$, $n = 0$).

white solid; mp 213°C; ^1H NMR (300 MHz, CD_3OD): δ 7.94-8.06 (m, 3, Ar-H), 7.54-7.74 (m, 6, Ar-H); 7.2-7.38 (m, 1, Ar-H); 3.5 (br, s, N- CH_3); MS (EI): m/e 433 (M^+ for free base); Anal.: ($\text{C}_{18}\text{H}_{15}\text{Br}_2\text{N}_3\cdot\text{HCl}$); Calcd. (%): C: 46.04, H: 3.43, N: 8.95; Found (%): C: 46.15, H: 3.33, N: 8.89.

Example 36 - N-(1-Naphthyl)-N'-(2-chloro-5-thiomethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{Cl}$, $\text{R}^4 = \text{SCH}_3$, $n = 0$).

white solid; mp 175°C; ¹H NMR (300 MHz, CD₃OD): δ 7.95-8.10 (m, 3, Ar-H), 7.55-7.70 (m, 4, Ar-H); 7.46-7.51 (d, J=8Hz; 1, Ar-H); 7.34-7.39 (s, 1, Ar-H); 7.25-7.32 (dd, 1, Ar-H); 2.51 (s, 3, S-CH₃); MS (EI): m/e 342 (M⁺ for free base); Anal.:

- 5 (C₁₈H₁₆ClN₃S•HCl•EtOH); Calcd. (%): C: 56.61, H: 5.23, N: 9.90; Found (%): C: 56.71, H: 5.21, N: 10.19.

Example 37 - N-(1-Naphthyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = F, R⁴ = CF₃, n = 0).

10

white solid; mp 149°C; ¹H NMR (300 MHz, CD₃OD): δ 7.97-8.07 (m, 3, Ar-H), 7.48-7.85 (m, 7, Ar-H); MS (EI): m/e 347 (M⁺ for free base); Anal.: (C₁₈H₁₃F₄N₃•HCl); Calcd. (%): C: 56.33, H: 3.68, N: 10.95; Found (%): C: 55.91, H: 3.69, N: 10.79.

15

Example 38 - N-(1-Naphthyl)-N'-(2-chloro-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = Cl, R⁴ = CF₃, n = 0).

- white solid; mp 198°C; ¹H NMR (300 MHz, CD₃OD): δ 8.07-8.09 (d, J=8.5Hz, 1, Ar-H), 7.98-8.01 (m, 2, Ar-H); 7.56-7.86 (m; 7, Ar-H); MS (EI): m/e 364 (M⁺ for free base); Anal.: (C₁₈H₁₃ClF₃N₃•HCl); Calcd. (%): C: 54.02, H: 3.53, N: 10.50; Found (%): C: 54.16, H: 3.52, N: 10.35.

20

Example 39 - N-(1-Naphthyl)-N'-(2-bromo-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = Br, R⁴ = CF₃, n = 0).

25

white solid; mp 234°C; ^1H NMR (300 MHz, CD_3OD): δ 8.10-8.12 (d, $J=9\text{Hz}$, 1, Ar-H), 7.97-8.01 (m, 3, Ar-H); 7.86 (s, 1, Ar-H); 7.56-7.70 (m, 5, Ar-H); MS (EI): m/e 408 (M^+ for free base); Anal.: ($\text{C}_{18}\text{H}_{13}\text{BrF}_3\text{N}_3\cdot\text{HCl}$); Calcd. (%): C: 48.62, H: 3.17, N: 9.45; Found (%): C: 48.49, H: 3.11, N: 9.18.

Example 40 - N-(1-Naphthyl)-N'-(2-thiomethyl-5-trifluoromethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of $\text{R} = 1\text{-naphthyl}$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{SCH}_3$, $\text{R}^4 = \text{CF}_3$, $n = 0$).

white solid; mp 210°C; ^1H NMR (300 MHz, CD_3OD): δ 8.11-8.14 (d, $J=8\text{Hz}$, 1, Ar-H), 7.98-8.01 (d, $J=7\text{Hz}$; 2, Ar-H); 7.55-7.73 (m, 7, Ar-H); 2.62 (3, s, S-CH_3); MS (EI): m/e 375 (M^+ for free base); Anal.: ($\text{C}_{19}\text{H}_{16}\text{F}_3\text{N}_3\text{S}\cdot\text{HCl}$); Calcd. (%): C: 55.41, H: 4.16, N: 10.20; Found (%): C: 55.27, H: 4.18, N: 10.90.

Example 41 - N-(1-Naphthyl)-N'-(2-methoxy-5-methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of $\text{R} = 1\text{-naphthyl}$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{OCH}_3$, $\text{R}^4 = \text{CH}_3$; $n = 0$).

white solid; mp 194°C; ^1H NMR (300 MHz, CD_3OD): δ 8.06-8.09 (d, $J=8\text{Hz}$, 1, Ar-H), 7.96-8.00 (m, 2, Ar-H); 7.52-7.69 (m, 4, Ar-H); 7.14-7.20 (m, 2, Ar-H); 7.02-7.05 (dd, $J=8.5\text{ Hz}$; 1, Ar-H); 3.94 (s, 3, OCH_3); 2.29 (3, s, Ar-CH_3); Anal.: ($\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}\cdot\text{HCl}$); Calcd. (%): C: 66.76, H: 5.90, N: 12.29; Found (%): C: 66.25, H: 5.89, N: 12.23.

Example 42 - N-(1-Naphthyl)-N'-(2-chloro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of $\text{R} = 1\text{-naphthyl}$, $\text{R}^1 = \text{R}^2 = \text{H}$, $\text{R}^3 = \text{Cl}$, $\text{R}^4 = \text{CH}_2\text{CH}_3$, $n = 0$).

white solid; mp 154°C; ¹H NMR (300 MHz, CD₃OD): δ 8.07-8.10 (d, J=9Hz, 1, Ar-H), 7.97-8.01 (m, 2, Ar-H); 7.57-7.69 (m, 4, Ar-H); 7.47-7.50 (d, J=8Hz, 1, Ar-H); 7.13-7.35 (m, 2, Ar-H); 2.63-2.71 (q, J=7.5Hz, 2, CH₂); 1.21-1.26 (t, J=8Hz, 3, CH₃); MS (EI): m/e 324 (M⁺ for free base).

Example 43 - N-(1-Naphthyl)-N'-(2-chloro-5-ethylphenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = H, R² = CH₃, R³ = Cl, R⁴ = CH₂CH₃, n = 0).

10 white solid; mp 233°C; ¹H NMR (300 MHz, CD₃OD): δ 7.97-8.02 (m, 3, Ar-H), 7.52-7.63 (m, 6, Ar-H); 7.31-7.34 (d, J=8Hz, 1, Ar-H); 3.51 (br s, 3, N-CH₃); 2.67-2.74 (q, J=7.5Hz, 2, CH₂); 1.24-1.29 (t, J=8Hz, 3, CH₃); MS (EI): m/e 338 (M⁺ for free base); Anal.: (C₂₀H₂₀ClN₃•HCl); Calcd. (%): C: 64.18, H: 5.65, N: 11.23; Found (%):

15 C: 63.96, H: 5.83, N: 11.25.

Example 44 - N-(1-Naphthyl)-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = Br, R⁴ = CH₂CH₃, n = 0).

20 white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, CD₃OD): δ 8.09-7.22 (m, 10H, Ar-H), 2.67 (q, J=7.5Hz, 2H, CH₂), 1.24 (t, J=7.5Hz, 3H, CH₃).

Example 45 - N-(1-Naphthyl)-N'-(2-fluoro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = F, R⁴ = CH₂CH₃, n = 0).

25

white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); ¹H NMR (300 MHz, CD₃OD): δ 8.05-7.19 (m, 10H, Ar-H), 2.65 (q, J = 7.5Hz, 2H, CH₂), 1.23 (t, J = 7.5Hz, 3H, CH₃).

- 5 **Example 46** - N-(1-Naphthyl)-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = Br, R⁴ = CH₂CH₃, n = 0).

white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); mp: 145-146°C; ¹H NMR (300 MHz, CD₃OD): δ 8.09-7.22 (m, 10H, Ar-H), 2.67 (q, J = 7.5Hz, 2H, CH₂), 1.24 (t, J = 7.5Hz, 3H, CH₃); MS (EI): m/e 367 (M⁺ for free base).

10

- Example 47** - N-(1-Naphthyl)-N'-(2-fluoro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, R¹ = R² = H, R³ = F, R⁴ = CH₂CH₃, n = 0).
- 15

white solid; TLC: R_f = 0.5 (10% MeOH/CH₂Cl₂); mp: 100-101°C; ¹H NMR (300 MHz, CD₃OD): δ 8.05-7.19 (m, 10H, Ar-H), 2.65 (q, J = 7.5Hz, 2H, CH₂), 1.23 (t, J = 7.5Hz, 3H, CH₃); MS (EI): m/e 307.1 (M⁺ for the free base); Anal.: (C₁₉H₁₈FN₃•HCl); Calcd. (%): C: 66.37, H: 5.57, N: 12.22; Found (%): C: 66.21, H: 5.50, N: 12.17.

20

- Example 48** - N-(8-Quinoliny)-N'-(2-chloro-5-methylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 8-quinoliny, R¹ = R² = H, R³ = Cl, R⁴ = CH₃, n = 0).
- 25 yellowish solid; mp 150°C; ¹H NMR (300 MHz, CD₃OD): δ 8.98-8.00 (dd, 1, Ar-H), 8.40-8.44 (dd, 1, Ar-H); 7.93-7.96 (d, 1, Ar-H); 7.82-7.84 (d, 1, Ar-H); 7.61-7.68 (m, 2, Ar-H); 7.38-7.44 (m, 3, Ar-H);

7.21-7.22 (d, 1, Ar-H); 3.30 (s, 3, CH₃); MS (EI): m/e 310 (M⁺ for free base).

Example 49 - N-(8-Quinoliny)-N'-(2-chloro-5-

5 ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=8-quinoliny, R¹=R²=H, R³=Cl, R⁴=CH₂CH₃, n=0).

brown solid; mp 167°C; ¹H NMR (300 MHz, CD₃OD): δ 8.40-9.25 (m, 2, Ar-H), 7.27-8.34 (m, 7, Ar-H); 2.65-2.72 (q, 2, CH₂); 1.22-1.27 (t, 3, CH₃); MS (EI): m/e 324 (M⁺ for free base).

10

Example 50 - N-(3-Ethylphenyl)-N-methyl-N'-(2,4,5-

trichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=CH₃, R²=H, R³=R⁴=Cl, R⁵=4-Cl, n=1).

white solid; TLC: R_f=0.3 (10% MeOH/CH₂Cl₂); mp: 164-165°C;

15 ¹H NMR (300 MHz, CD₃OD): δ 7.79-7.23 (m, 6H, Ar-H), 3.49 (s, 3H, CH₃), 2.70 (q, J=7.6Hz, 2H, CH₂), 1.26 (t, J=7.6Hz, 3H, CH₃); MS (EI): m/e 335.0 (M⁺ for the free base); Anal.: (C₁₆H₁₆Cl₃N₃•HCl•1/2H₂O); Calcd. (%): C: 47.78, H: 4.51, N: 10.45; Found (%): C: 47.93, H: 4.63, N: 10.33.

20

Example 51 - N-(3-Ethylphenyl)-N'-(2,4,5-

trichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-ethylphenyl, R¹=R²=H, R³=R⁴=Cl, R⁵=4-Cl, n=1).

white solid; TLC: R_f=0.4 (10% MeOH/CH₂Cl₂); mp: 82-83°C; ¹H

25 NMR (300 MHz, CD₃OD): δ 7.63-7.18 (m, 6H, Ar-H), 2.63 (q, J=7.6Hz, 2H, CH₂), 1.22 (t, J=7.6Hz, 3H, CH₃); MS (EI): m/e 341 (M⁺ for the free base).

Example 52 - N-(1-Naphthyl)-N'-(2,4,5-trichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 1-naphthyl, $R^1 = R^2 = H$, $R^3 = R^4 = Cl$, $R^5 = 4-Cl$, $n = 1$).

white solid; TLC: $R_f = 0.4$ (10% MeOH/CH₂Cl₂); mp: 238-239°C;

- 5 ¹H NMR (300 MHz, CD₃OD): δ 8.08-7.58 (m, 10H, Ar-H); MS (EI): m/e 363 (M⁺ for the free base); Anal.: (C₁₇H₁₂Cl₃N₃•HCl); Calcd. (%): C: 50.9, H: 3.29, N: 10.48; Found (%): C: 51.11, H: 3.33, N: 10.63.

Example 53 - N-(3-Ethylphenyl)-N-methyl-N'-(2-bromo-5-

- 10 methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-ethylphenyl, $R^1 = CH_3$, $R^2 = H$, $R^3 = Br$, $R^4 = CH_3S$, $n = 0$).

TLC: $R_f = 0.5$ (SiO₂, CH₂Cl₂/MeOH = 10/1); M.P.: 90-92°C; ¹H

NMR (CD₃OD): δ (ppm) 7.64-7.15 (m, Ar-H, 7H), 3.49 (s, CH₃, 3H), 2.70 (q, J = 7.4 Hz, 2H, CH₂), 2.47 (s, SCH₃, 3H), 1.25 (t, J = 7.5 Hz,

- 15 3H, CH₃); MS (EI): m/e 377 (M⁺: C₁₇H₂₀N₃Br₁S₁); Anal. (C₁₇H₂₀N₃Br₁S₁•HCl); Calcd. (%): C: 49.23, H: 5.1, N: 10.13; Found (%) C: 49.30, H: 5.28, N: 10.28.

Example 54 - N-(3-Methylthiophenyl)-N-methyl-N'-(2,5-

- 20 dichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-methylthiophenyl, $R^1 = CH_3$, $R^2 = H$, $R^3 = R^4 = Cl$, $n = 0$).

TLC: $R_f = 0.3$ (10% MeOH/CH₂Cl₂); MP: 200-201°C; ¹H NMR

(300 MHz, CD₃OD): δ (ppm) 7.55-7.15 (m, 7H, Ar-H), 3.49 (s, 3H, NCH₃), 2.52 (s, 3H, SCH₃); MS (EI): m/e 339 (M⁺ for the free base);

- 25 Anal. (C₁₅H₁₅Cl₂N₃S•HCl); Calcd. (%): C: 47.82, H: 4.28, N: 11.15; Found (%): C: 47.66, H: 4.26, N: 11.34.

Example 55 - N-(3-Methylthiophenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-methylthiophenyl, R¹ = CH₃, R² = H, R³ = R⁴ = Br, n = 0).

TLC: R_f = 0.4 (10% MeOH/CH₂Cl₂); MP: 239-240°C; ¹H NMR: δ (ppm) 7.70-7.20 (m, 7H, Ar-H), 3.49 (s, 3H, NCH₃), 2.53 (s, 3H, SCH₃); MS (EI): m/e 429 (M⁺ for the free base); Anal. (C₁₅H₁₅Br₂N₃S•HCl); Calcd. (%): C: 38.69, H: 3.46, N: 9.02; Found (%): C: 38.65, H: 3.60, N: 8.98.

10 Example 56 - N-(3-Methylthiophenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-methylthiophenyl, R¹ = CH₃, R² = H, R³ = Cl, R⁴ = CH₂CH₃, n = 0).
white solid; TLC: R_f = 0.3 (10% MeOH/CH₂Cl₂); MP: 212-213°C;
¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.45-7.19 (m, 7H, Ar-H), 3.49 (s,
15 3H, CH₃), 2.68 (q, J = 7.5Hz, 2H, CH₂), 2.51 (s, 3H, SCH₃), 1.22 (t,
J = 7.5Hz, 3H, CH₃); MS (EI): m/e 333 (M⁺ for the free base); Anal. (C₁₇H₂₀ClN₃S•HCl); Calcd. (%): C: 55.14, H: 5.72, N: 11.35; Found (%): C: 55.29, H: 5.81, N: 11.36.

20 Example 57 - N-(3-Methylthiophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-methylthiophenyl, R¹ = CH₃, R² = H, R³ = Cl, R⁴ = SCH₃, n = 0).
TLC: R_f = 0.25 (10% MeOH/CH₂Cl₂); MP: 203-204°C; ¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.50-7.18 (m, 7H, Ar-H), 3.49 (s, 3H,
25 CH₃), 2.52 (s, 3H, SCH₃), 2.49 (s, 3H, SCH₃); MS (EI): m/e 351 (M⁺ for the free base); Anal. (C₁₆H₁₈ClN₃S₂•HCl); Calcd. (%): C: 49.48, H: 4.93, N: 10.82; Found (%): C: 49.41, H: 5.07, N: 10.81.

Example 58 - N-(3-Methylthiophenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine (Formula I: R = 3-methylthiophenyl, R¹ = CH₃, R² = H, R³ = Br, R⁴ = SCH₃, n = 0).

TLC: R_f = 0.43 (SiO₂, CH₂Cl₂/MeOH = 10/1); M.P.: 174-175°C; ¹H NMR (CD₃OD): δ (ppm) 7.65-7.15 (m, Ar-H, 7H), 3.49 (s, CH₃, 3H), 2.52 (s, SCH₃, 3H), 2.49 (s, SCH₃, 3H); HRMS: 395.0120 (Calcd.: 395.0126 for C₁₆H₁₈N₃BrS₂); HPLC: 98.47%.

Example 59 - N-(3-Methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-methylthiophenyl, R¹ = CH₃, R² = H, R³ = Br, R⁴ = CH₂CH₃, n = 0).

TLC: R_f = 0.3 (10% MeOH/CH₂Cl₂); MP: 199-200°C; ¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.65-7.15 (m, 7H, Ar-H), 3.49 (s, 3H, CH₃), 2.64 (q, J = 7.5Hz, 2H, CH₂), 2.52 (s, 3H, SCH₃), 1.23 (t, J = 7.5Hz, 3H, CH₃); MS (EI): m/e 378 (M⁺ for the free base); Anal. (C₁₇H₂₀BrN₃S•HCl); Calcd. (%): C: 49.23, H: 5.10, N: 10.13; Found (%): C: 49.39, H: 5.01, N: 10.02.

Example 60 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethylphenyl, R¹ = CH₃, R² = H, R³ = R⁴ = Cl, n = 0).

TLC: R_f = 0.3 (10% MeOH/CH₂Cl₂); MP: 209-210°C; ¹H NMR: δ (ppm) 7.86-7.39 (m, 7H, Ar-H); 3.54 (s, 3H, CH₃); MS (EI): m/e 361 (M⁺ for the free base); Anal. (C₁₈H₁₂Cl₂F₃N₃•HCl); Calcd. (%): C: 45.19, H: 3.29; N: 10.54; Found (%): C: 45.31, H: 3.50, N: 10.61.

Example 61 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethylphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = R^4 = \text{Br}$, $n = 0$).

TLC: $R_f = 0.5$ (10% MeOH/ CH_2Cl_2); MP: 233-234°C; ^1H NMR: δ (ppm) 7.90-7.45 (m, 7H, Ar-H); 3.54 (s, 3H, CH_3); MS (EI): m/e 449 (M^+ for the free base); Anal. ($\text{C}_{15}\text{H}_{12}\text{Br}_2\text{F}_3\text{N}_3 \cdot \text{HCl}$); Calcd. (%): C: 36.93, H: 2.69, N: 8.62; Found (%): C: 37.00, H: 2.70, N: 8.56.

Example 62 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethylphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{SCH}_3$, $n = 0$).

TLC: $R_f = 0.3$ (10% MeOH/ CH_2Cl_2); MP: 156-157°C; ^1H NMR (300 MHz, CD_3OD): δ (ppm) 7.90-7.20 (m, 7H, Ar-H), 3.53 (s, 3H, CH_3), 2.49 (s, 3H, SCH_3); MS (EI): m/e 373 (M^+ for the free base); Anal. ($\text{C}_{16}\text{H}_{15}\text{ClF}_3\text{N}_3\text{S}_2 \cdot \text{HCl}$); Calcd. (%): C: 46.84, H: 3.93, N: 10.24; Found (%): C: 46.78, H: 4.07, N: 10.12.

Example 63 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethylphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{CH}_2\text{CH}_3$, $n = 0$).

TLC: $R_f = 0.3$ (10% MeOH/ CH_2Cl_2); MP: 164-165°C; ^1H NMR (300 MHz, CD_3OD): δ (ppm) 7.83-7.19 (m, 7H, Ar-H), 3.53 (s, 3H, CH_3), 2.65 (q, $J = 7.5\text{Hz}$, 2H, CH_2), 1.22 (t, $J = 7.5\text{Hz}$, 3H, CH_3); MS (EI): m/e 355 (M^+ for the free base); Anal. ($\text{C}_{17}\text{H}_{17}\text{ClF}_3\text{N}_3 \cdot \text{HCl}$); Calcd. (%): C: 52.06, H: 4.63, N: 10.71; Found (%): C: 52.14, H: 4.79, N: 10.66.

Example 64 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-trifluoromethylphenyl, R¹=CH₃, R²=H, R³=Br, R⁴=SCH₃, n=0).

5 TLC: R_f=0.5 (10% MeOH/CH₂Cl₂); MP: 121-122°C; ¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.87-7.15 (m, 7H, Ar-H), 3.53 (s, 3H, CH₃), 2.49 (s, 3H, CH₃); MS (EI): m/e 419 (M⁺ for the free base); Anal. (C₁₆H₁₅BrF₃N₃S•HCl); Calcd. (%): C: 42.26, H: 3.5, N: 9.24; Found (%): C: 42.27, H: 3.70, N: 9.06.

10

Example 65 - N-(3-Trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-trifluoromethylphenyl, R¹=CH₃, R²=H, R³=Br, R⁴=CH₂CH₃, n=0).

15 TLC: R_f=0.5 (10% MeOH/CH₂Cl₂); MP: 95-96°C; ¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.70-6.75 (m, 7H, Ar-H), 3.47 (s, 3H, CH₃), 2.58 (q, J=7.5Hz, 2H, CH₂), 1.22 (t, J=7.5Hz, 3H, CH₃); MS (EI): m/e 401 (M⁺ for the free base); Anal. (C₁₇H₁₇BrF₃N₃•HCl); Calcd. (%): C: 46.76, H: 4.15, N: 9.62; Found (%): C: 46.57, H: 4.43, N: 9.38.

20 Example 66 - N-(3-Bromophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R=3-bromophenyl, R¹=CH₃, R²=H, R³=Cl, R⁴=SCH₃, n=0).

25 TLC: R_f=0.5 (10% MeOH/CH₂Cl₂); MP: 244-245°C; ¹H NMR (300 MHz, CD₃OD): δ (ppm) 7.80-7.20 (m, 7H, Ar-H), 3.53 (s, 3H, CH₃), 2.49 (s, 3H, SCH₃); MS (EI): m/e 385 (M⁺ for the free base); Anal. (C₁₅H₁₅BrClN₃S•HCl); Calcd. (%): C: 42.78, H: 3.83, N: 9.98; Found (%): C: 42.85, H: 3.99, N: 9.80.

Example 67 - N-(3-Trifluoromethoxyphenyl)-N'-(2-bromo-5-ethylphenyl)-N-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethoxyphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Br}$, $R^4 = \text{CH}_2\text{CH}_3$, $n = 0$).

5 TLC: $R_f = 0.36$ (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10/1$); MP: 74-75°C; ^1H NMR (CD_3OD): δ (ppm) 7.63-7.15 (m, Ar-H, 7H), 3.30 (s, CH_3 , 3H), 2.64 (m, CH_2 , 2H), 1.23 (t, CH_3 , $J = 7.45\text{Hz}$, 3H); MS (EI): m/e 416.0 (M^+ : $\text{C}_{17}\text{H}_{17}\text{N}_3\text{BrOF}_3$); Anal. ($\text{C}_{17}\text{H}_{17}\text{N}_3\text{BrOF}_3 \cdot \text{HCl}$); Calcd. (%): C: 45.10, H: 4.01, N: 9.28; Found (%): C: 45.31, H: 4.15, N: 9.09.

10

Example 68 - N-(3-Trifluoromethoxyphenyl)-N'-(2,5-dibromophenyl)-N-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-trifluoromethoxyphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = R^4 = \text{Br}$, $n = 0$).

15 TLC: $R_f = 0.55$ (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10/1$); MP: 188-189°C; ^1H NMR (CD_3OD): δ (ppm) 7.80-7.40 (m, Ar-H, 7H), 3.52 (s, CH_3 , 3H); MS (EI): m/e 467.80 (M^+ : $\text{C}_{15}\text{H}_{12}\text{N}_3\text{Br}_2\text{OF}_3$); Anal. ($\text{C}_{15}\text{H}_{12}\text{N}_3\text{Br}_2\text{OF}_3 \cdot \text{HCl}$); Calcd. (%): C: 35.78, H: 2.60, N: 8.34; Found (%): C: 35.72, H: 2.75, N: 8.26.

20

Example 69 - N-(3-Methylsulfonylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula II: hydrochloride salt of R = 3-methylsulfonylphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = R^4 = \text{Br}$, $n = 0$).

25 TLC: $R_f = 0.47$ (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10/1$); MP: 245-246°C; ^1H NMR (CD_3OD): δ (ppm) 8.15-7.45 (m, Ar-H, 7H), 3.56 (s, CH_3 , 3H), 3.17 (s, CH_3 , 3H); MS (EI): m/e 462 (M^+ : $\text{C}_{15}\text{H}_{15}\text{N}_3\text{Br}_2\text{SO}_2$); Anal. ($\text{C}_{15}\text{H}_{15}\text{N}_3\text{Br}_2\text{SO}_2 \cdot \text{HCl}$); Calcd. (%): C: 36.20, H: 3.24, N: 8.44; found (%): C: 35.98, H: 3.11, N: 8.36.

Example 70 - N-(3-Methylsulfinylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine hydrochloride (Formula II: hydrochloride salt of R = 3-methylsulfinylphenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = R^4 = \text{Br}$, $n = 0$).

TLC: $R_f = 0.52$ (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10/1$); MP: 169-170°C; ^1H NMR (CD_3OD): δ (ppm) 7.90-7.45 (m, Ar-H, 7H), 3.55 (s, CH_3 , 3H), 2.85 (s, CH_3 , 3H); MS (EI): m/e 446 (M^+ : $\text{C}_{15}\text{H}_{15}\text{N}_3\text{Br}_2\text{SO}$); Anal. ($\text{C}_{15}\text{H}_{15}\text{N}_3\text{Br}_2\text{SO} \cdot \text{HCl}$); Calcd. (%): C: 37.41, H: 3.35, N: 8.72; Found (%): C: 37.15, H: 3.46, N: 8.38.

10 Example 71 - N-(3-Iodophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = iodophenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{SCH}_3$, $n = 0$).

M.P.: 61-63°C.

15 Example 72 - N-(2-Chloro-5-ethylphenyl)-N'-(3-iodophenyl)guanidine hydrochloride (Formula I: hydrochloride salt of R = 3-iodophenyl, $R^1 = R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{CH}_2\text{CH}_3$, $n = 0$).
white solid; mp 76-77°C; $R_f = 0.28$ (10:1 $\text{CHCl}_3/\text{MeOH}$): ^1H NMR (300 MHz, CD_3OD): δ (ppm) 7.76-7.78 (m, 1H, Ar-H), 7.52-7.56 (m, 1H, Ar-H), 7.39-7.42 (d, $J = 6\text{Hz}$, 1H, Ar-H), 7.31-7.36 (m, 1H, Ar-H), 7.08-7.22 (m, 3H, Ar-H), 3.30 (q, 2H, CH_2), 1.20-1.30 (t, 3H, CH_3); MS(EI): m/e 400 (M^+ for free base); Anal.: ($\text{C}_{15}\text{H}_{16}\text{Cl}_2\text{IN}_3 \cdot \text{HCl}$); Calcd. (%): C: 41.31, H: 3.70, N: 9.63; Found (%): c: 44.60, H: 3.96, N: 9.59.

25

Example 73 - N-(2-chloro-5-thiomethylphenyl)-N'-(3-iodophenyl)-N'-methylguanidine hydrochloride (Formula I: hydrochloride salt of R = 3-iodophenyl, $R^1 = \text{CH}_3$, $R^2 = \text{H}$, $R^3 = \text{Cl}$, $R^4 = \text{SCH}_3$, $n = 0$).

brown solid; mp 61-63°C; R_f = 0.24 (10:1) $\text{CHCl}_3/\text{MeOH}$; ^1H NMR (300 MHz, CD_3OD): δ 7.74-7.75 (3, 1H, Ar-H), 7.58-7.62 (dt, 1H, Ar-H), 7.30-7.37 (m, 2H, Ar-H), 7.14-7.19 (t, 1H, Ar-H), 6.92-6.97 (m, 2H, Ar-H), 3.36 (s, 3H, N- CH_3), 2.46 (s, 3H, S- CH_3); MS (EI): m/e 432 (M⁺ for free base); Anal. ($\text{C}_{15}\text{H}_{15}\text{ClN}_3\text{S}\cdot\text{HCl}\cdot\text{Et}_2\text{O}$); Calcd. (%): C: 40.76, H: 4.33, N: 8.20; Found (%): C: 44.37, H: 4.69, N: 8.58.

EXAMPLE 74 - PCP Radioligand Binding Assays

PCP receptor binding assays were performed using rat brain membranes as the source of receptors. The radioligand used to label PCP receptors was [^3H]MK-801.

Synthesis of [^3H]MK-801 and PCP receptor binding assay protocols are described in J.F.W. Keana, et al., Life Sci., **43**:965-973 (1988). Briefly, in the protocols, rat brain membranes were prepared and used as described for "detergent-treated membranes" (see D.E. Murphy, et al., *J. Pharmacol. Exp. Ther.*, **240**:778-784 (1987)), and stored at a protein concentration of 10 mg/ml at -70°C. No effect of storage (1 month) of the membranes at -70°C on receptor number or affinity for [^3H]MK-801 was observed.

For assays with rat membranes, the thawed membranes were incubated at 1 mg/ml with 0.01% Triton X-100 for 15 minutes at 32°C, then washed three times by centrifugation to reduce the endogenous amino acid concentrations, and finally resuspended in buffer for assay. Glycine and 1-glutamate were each added back to a final concentration of 1 μM to maximally stimulate the [^3H]MK-801 binding. The assays contain 400 μl of membranes, and 50 μl of buffer or unlabelled drug.

For [³H]MK-801 binding, 1 nm radioligand was incubated with 200 µg/ml of rat brain membranes for 4 hours at room temperature. All assays were stopped by rapid filtration under vacuum through Whatman GF/B glass fiber filters presoaked in 0.05% polyethyleneimine using a
5 Brandel 48-well cell harvester (Brandel, Gaithersburg, MD). The filters were washed three times with 5 ml of cold 5 mM tris-HCl, pH = 7.4. Each filter was suspended in 10 ml of Cytoscint (ICN Biomedicals, Costa Mesa, CA) and radioactivity was measured by liquid scintillation spectrometry at a counting efficiency of 50%. Nonspecific binding was
10 defined as that remaining in the presence of 10 µM MK-801 or 100 µM PCP.

Saturation data were evaluated and IC₅₀ values were determined as described by J.B. Fischer and A. Schonbrunn (*J. Biol. Chem.*,
15 263:2808-2816 (1988)). K_i values are derived from the IC₅₀ values as described by Cheng et al., *Biochem. Pharmacol.*, 22:3099-3108 (1973).

Results of the assay are shown in Table I which follows Example 75 below, wherein the general formula of the tested compounds (i.e.,
20 compounds identified as compound nos. 1-83) is shown at the top of Table I with the particular substituent groups of each compound specified within the Table.

EXAMPLE 75 - Sigma Receptor Binding Assay

25 Methods. Sigma receptor binding assays using guinea pig brain membrane homogenates and the radioligand [³H]DTG were conducted as described by E. Weber, et al., *P.N.A.S. (USA)*, 83:8784-8788 (1986). Briefly, frozen whole guinea-pig brains (Biotrol, Indianapolis, IN) were


homogenized in 10 volumes (w/v) of ice-cold 320 mM sucrose using a Brinkman polytron. The homogenate was centrifuged at 1,000 x g for 20 minutes at 4°C. The supernatant was centrifuged at 20,000 x g for 20 minutes at 4°C. The resulting pellet was resuspended in 10 initial
5 volumes of 50 mM Tris/HCl buffer at pH 7.4 and centrifuged at 20,000 x g for 20 minutes at 4°C. The resulting pellet was resuspended in 5 initial volumes ice-cold 50 mM Tris/HCl (pH 7.4), and the final volume was adjusted to yield a protein concentration of 3 mg/ml. Aliquots of 20-ml were stored at -70°C until used, with no detectable loss of
10 binding.

For [³H]DTG binding assays, the frozen membrane suspensions were thawed and diluted 1:3 in 50 mM Tris/HCl (pH 7.4). To 12 x 75 mm polystyrene test tubes were added 0.8 ml of diluted membrane
15 suspension, 0.1 ml of [³H]DTG (Dupont/NEN) to yield a final concentration of 1.4 nM, and 0.1 ml of unlabelled drugs or buffer. The protein concentration in the 1-ml final incubation volume was 800 µg/ml, corresponding to 32 mg of brain tissue (original wet weight) and to a tissue concentration within the linear range for specific binding.

20 Non-specific binding was defined as that remaining in the presence of 10 µM haloperidol. Incubations were terminated after 90 minutes at room temperature by addition of 4 ml of ice-cold 50mM Tris/HCl (pH 7.4) and rapid filtration of the membrane suspension through Whatman GF/B glass-fiber filters under vacuum, using a 48-well cell harvester

25 (Brandel). The filters were washed 2 times with 4 ml of 50 mM Tris/HCl (pH 7.4). Each filter was suspended in 10 ml Cytoscint (ICI), and radioactivity was measured by liquid scintillation spectrometry at a counting efficiency of approximately 50%. IC₅₀ values were determined

by non-linear regression analysis. The results are shown in Table I below for each of the tested compounds of the specified structure. In Table I, the designation "NT" indicates the compound was not tested in the specified assay.

TABLE I

Compd. No.	R	R¹	R²	R³	R⁴	[³H-MK801]		[³H-DTG] IC ₅₀ (nM)
						IC ₅₀ (nM)	K _i (nM)	
1	3-ethylphenyl	H	H	Cl	Cl	88	67.7	11.8
2	3-ethylphenyl	H	H	Br	Br	87.5	67.3	18.2
3	3-ethylphenyl	H	H	H	Cl	146	112	15.5
4	3-ethylphenyl	H	H	Br	CF ₃	86.9	66.8	10.3
5	3-ethylphenyl	H	H	F	CF ₃	98.9	76.0	14.8
6	3-ethylphenyl	H	H	Cl	CF ₃	57.1	43.9	14.2
7	3-ethylphenyl	H	H	Cl	CH ₃	100	76.9	30.6
8	3-ethylphenyl	H	H	Cl	CH ₂ CH ₃	45.2	34.7	2.04
9	3-ethylphenyl	H	H	H	CH ₂ CH ₃	168	129	8.0
10	3-ethylphenyl	CH ₃	H	Cl	Cl	84.6	65.0	28.5
11	3-ethylphenyl	CH ₃	H	Br	Br	47.6	36.6	40.2
12	3-ethylphenyl	CH ₃	H	H	Cl	646	497	43.5
13	3-ethylphenyl	CH ₃	H	Br	CF ₃	102	78.4	208
14	3-ethylphenyl	CH ₃	H	F	CF ₃	252	194	85
15	3-ethylphenyl	CH ₃	H	Cl	CF ₃	131	101	120
16	3-ethylphenyl	CH ₃	H	Cl	CH ₃	101	77.6	45.3
17	3-ethylphenyl	CH ₃	H	Cl	CH ₂ CH ₃	53	40.7	115
18	3-ethylphenyl	CH ₃	H	H	CH ₂ CH ₃	213	164	81.8
19	3-ethylphenyl	CH ₃	H	H	Br	105	80.7	40

TABLE I (continued)


Compd. No.	R	R ¹	R ²	R ³	R ⁴	[³ H-MK801]		[³ H-DTG] IC ₅₀ (nM)
						IC ₅₀ (nM)	K _i (nM)	
20	3-ethylphenyl	CH ₃	H	F	CH ₂ CH ₃	126	96.9	112.5
21	3-ethylphenyl	H	H	F	CH ₂ CH ₃	64.8	49.8	7.4
22	3-ethylphenyl	CH ₃	H	Br	CH ₂ CH ₃	16.7	12.8	203
23	3-ethylphenyl	H	H	Br	CH ₂ CH ₃	38.3	24.9	5.07
24	3-ethylphenyl	CH ₃	H	Cl	SCH ₃	6.7	5.1	309.5
25	3-ethylphenyl	H	H	Cl	SCH ₃	15.4	11.8	15.8
26	3-ethylphenyl	CH ₃	CH ₃	Cl	Cl	93.7	72.0	39.3
27	3-ethylphenyl	CH ₃	CH ₃	Br	Br	35.5	27.3	380
28	3-ethylphenyl	CH ₃	CH ₃	Cl	CH ₂ CH ₃	145	112	240.5
29	2-chloro-5-ethylphenyl	H	H	Cl	CH ₃	54.7	42.1	36.1
30	2-chloro-5-ethylphenyl	H	H	Br	Br	66.4	51.0	186
31	1-naphthyl	H	H	Cl	Cl	41	31.5	25
32	1-naphthyl	H	H	Br	Br	48.6	37.3	37.6
33	1-naphthyl	H	H	CH ₃	CH ₃	79.2	60.9	27.4
34	1-naphthyl	H	H	F	CH ₃	86	66.1	69
35	1-naphthyl	H	H	Cl	CH ₃	31.2	24.0	43
36	1-naphthyl	H	H	OCH ₃	CH ₃	61.5	47.3	161
37	1-naphthyl	H	H	H	Cl	371	285	33
38	1-naphthyl	H	H	H	CH ₃	192	148	75
39	1-naphthyl	H	H	F	CF ₃	38.4	29.5	79.4
40	1-naphthyl	H	H	Cl	CF ₃	38.6	29.6	52.5
41	1-naphthyl	H	H	Br	CF ₃	51.1	39.3	49.6
42	1-naphthyl	H	H	SCH ₃	CF ₃	170	131	418
43	1-naphthyl	H	H	H	CF ₃	129	99.2	238
44	1-naphthyl	H	H	Cl	CH ₂ CH ₃	20.6	15.8	4.94
45	1-naphthyl	H	H	H	CH ₂ CH ₃	39	30.0	53.8
46	1-naphthyl	H	H	Cl	SCH ₃	43	33.2	25.4
47	1-naphthyl	H	H	H	SCH ₃	124	95.3	27
48	8-quinoliny	H	H	Cl	CH ₃	32	24.4	989
49	8-quinoliny	H	H	Cl	CH ₂ CH ₃	4.2	3.2	322
50	1-naphthyl	H	CH ₃	Cl	Cl	62	47.6	1318
51	1-naphthyl	H	CH ₃	Br	Br	65	49.9	1250
52	1-naphthyl	H	CH ₃	H	Cl	107	82.3	2982

TABLE I (continued)

Compd. No.	R	R ¹	R ²	R ³	R ⁴	[³ H-MK801]		[³ H-DTG] IC ₅₀ (nM)
						IC ₅₀ (nM)	K _i (nM)	
53	1-naphthyl	H	CH ₃	H	Br	54	41.6	2759
54	1-naphthyl	H	CH ₃	CH ₃	CH ₃	79	60.8	1554
55	1-naphthyl	H	CH ₃	Cl	CH ₃	41	31.6	2425
56	1-naphthyl	H	CH ₃	H	CH ₃	85	65.4	1262
57	1-naphthyl	H	CH ₃	Cl	CH ₂ CH ₃	32.8	25.2	136
58	1-naphthyl	H	CH ₃	H	CH ₂ CH ₃	37.5	28.8	2535
59	3-ethylphenyl	CH ₃	H	Br	CH ₃	3.19	2.45	240
60	3-methylthiophenyl	CH ₃	H	Cl	SCH ₃	2.43	1.84	480
61	3-methylthiophenyl	CH ₃	H	Cl	CH ₂ CH ₃	12.6	9.69	178
62	3-methylthiophenyl	CH ₃	H	Cl	Cl	59.3	45.6	130
63	3-methylthiophenyl	CH ₃	H	Br	SCH ₃	2.15	1.65	NT
64	3-methylthiophenyl	CH ₃	H	Br	CH ₂ CH ₃	5.09	3.92	180
65	3-methylthiophenyl	CH ₃	H	Br	Br	5.38	4.13	113
66	3-trifluoromethyl-phenyl	CH ₃	H	Cl	SCH ₃	8.47	6.92	421
67	3-trifluoromethyl-phenyl	CH ₃	H	Cl	CH ₂ CH ₃	77.0	59.2	200
68	3-trifluoromethyl-phenyl	CH ₃	H	Cl	Cl	201	155	110
69	3-trifluoromethyl-phenyl	CH ₃	H	Br	SCH ₃	5.55	4.27	631
70	3-trifluoromethyl-phenyl	CH ₃	H	Br	CH ₂ CH ₃	20.4	15.7	166
71	3-trifluoromethyl-phenyl	CH ₃	H	Br	Br	34.0	26.1	224
72	3-bromophenyl	CH ₃	H	Cl	SCH ₃	4.65	3.58	NT
73	3-trifluoro-methoxyphenyl	CH ₃	H	Br	Br	25.6	19.7	NT
74	3-trifluoro-methoxyphenyl	CH ₃	H	Br	CH ₂ CH ₃	16.0	12.3	NT
75	3-methyl-sulfonylphenyl	CH ₃	H	Br	Br	530	408	NT
76	3-methyl-sulfinylphenyl	CH ₃	H	Br	Br	322	248	NT
77	3-iodophenyl	CH ₃	H	Cl	SCH ₃	2.11	1.62	NT
78	3-iodophenyl	H	H	Cl	CH ₂ CH ₃	13.7	10.5	NT
79	8-quinoliny	CH ₃	H	Cl	SCH ₃	22.3	17	542

EXAMPLE 76 - *In vivo* assay for protection against NMDA-induced excitotoxic damage to the central nervous system.

The *in vivo* potency of compounds of the present invention is exemplified by data summarized in Table II and obtained pursuant to the following protocol. Day 7 neonatal rats were anesthetized with metophane inhalation anesthetic for 4-6 minutes, inserted into a stereotaxic apparatus and injected intrastrially with 0.5 μ l of 50 mM NMDA (N-methyl-D-aspartate). 15 minutes after the NMDA injection, the rat pups were injected intraperitoneally with 10, 30 or 60 μ mol/kg of the NMDA antagonist of the structure specified in Table II. Animals were returned to their mother and watched for signs of distress (e.g., respiratory depression). After five days, the animals were anesthetized with CO₂ and then decapitated; their brains were removed and weighed to determine the degree of neuroprotection. Because NMDA injection results in a retardation of brain growth (including necrosis), effects can be measured gravimetrically in terms of the weights of injected and non-injected hemispheres. Two groups of rat pups were used at each of three doses of a compound to generate a neuroprotection dose-response curve. The chemical structure of each of the tested compounds is specified below with the general formula of the compounds shown at the top of Table II with particular substituent groups specified within that Table. Table II discloses 1) the ED₈₀ for each tested compound, i.e., the dose of a compound that provides 80% of the maximum protection against damage to the central nervous system; and 2) the percent (%) maximum protection against damage to the central nervous system provided by the indicated dose expressed as μ mol per kilogram bodyweight of the test subject.


TABLE II

Cmpd. No.	R	R ₁	R ₂	R ₃	R ₄	ED80 μmol/kg	% maximum protection per dose (μmol/kg)
1	3-ethylphenyl	CH ₃	H	Cl	Cl	36.4	88.8@60
2	3-ethylphenyl	CH ₃	H	Br	Br	13.4	93.8@60
3	3-ethylphenyl	H	H	F	CF ₃	15.2	76.6@60
4	3-ethylphenyl	CH ₃	H	Cl	C ₂ H ₅	19.8	77.8@60
5	1-naphthyl	H	CH ₃	Cl	C ₂ H ₅	22.3	92.2@60
6	1-naphthyl	H	CH ₃	Br	Br	26.9	85.7@60
7	1-naphthyl	H	CH ₃	CH ₃	CH ₃	22.5	86.0@30
8	1-naphthyl	H	H	F	CF ₃	28.8	96.0@60
9	1-naphthyl	H	H	Cl	SCH ₃	10.8	92.7@60
10	1-naphthyl	H	H	Cl	CH ₃	45.8	96.4@60
11	8-quinolyl	H	H	Cl	C ₂ H ₅	14.2	94.5@30

This invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention.

What is claimed is:

1. A compound of the following Formula I:



wherein R, R¹ and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;


R³, R⁴, and each R⁵ substituent are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; n is an integer of from 0-3; or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein at least one of R and R¹ is other than hydrogen.

3. A compound of claim 2 wherein R is a substituted or unsubstituted carbocyclic aryl group or a substituted or unsubstituted heteroaromatic group.

4. A compound of claim 1 where R is a substituted or unsubstituted carbocyclic aryl group, and R¹ and R² are each independently hydrogen or substituted or unsubstituted alkyl.

5. A compound of claim 1 of the following Formula Ia:




wherein R and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R³, R⁴, each R⁵, R^{3'}, R^{4'}, and each R^{5'} are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted

alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; m and n are each independently an integer of from 0 to 3; or a pharmaceutically acceptable salt thereof.


6. A compound of claim 1 of the following Formula Ib:



wherein R, R¹ and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R³ and R⁴ are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1 of the following Formula Ic:



wherein R and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R^{3'}, R^{4'}, R^{3''} and each R^{5'} are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; n is an integer of from 0 to 3; or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 that is N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)-N'-methylguanidine;

N-(3-ethylphenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,5-dibromophenyl)-N'-methylguanidine;
N-(3-ethylphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-methylphenyl);
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-methylthio)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-methylthio)guanidine;

N-(1-naphthyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-ethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-methylphenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,4,5-trichlorophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,4,5-trichlorophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2,3,5-trichlorophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2,3,5-trichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2,4,5-trichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2,3,5-trichlorophenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dichlorophenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2-chloro-5-methylphenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dimethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-methylphenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2,5-dimethylphenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)-N-methylguanidine;
N-(1-naphthyl)-N'-(2,5-dibromophenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-(2-chloro-5-thiomethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-fluoro-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-bromo-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-thiomethyl-5-trifluoromethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-methoxy-5-methylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(1-naphthyl)-N'-(2-chloro-5-ethylphenyl)-N'-methylguanidine;
N-(1-naphthyl)-N'-methyl-N'-(2-chloro-5-thiomethylphenyl)guanidine;N-(8-quinoliny)-N'-(2-chloro-5-methylphenyl)guanidine;

N-(8-quinoliny)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(8-quinoliny)-N'-methyl-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;

N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2,5-dichlorophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-methylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;

N-(3-bromophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-bromophenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-bromophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-methyl-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-trifluoromethoxyphenyl)-N'-(2-bromo-5-ethylphenyl)guanidine;
N-(3-iodophenyl)-N-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-iodophenyl)-N'-methyl-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-iodophenyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
N-(3-iodophenyl)-N-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-iodophenyl)-N'-methyl-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-iodophenyl)-N'-(2-chloro-5-ethylphenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;
N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-ethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-ethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethylthiophenyl)guanidine;


N-(3-methylthiophenyl)-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethylthiophenyl)guanidine;

N-(3-methylthiophenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N'-(2-chloro-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-chloro-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-chloro-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-chloro-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N'-(2-bromo-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N-methyl-N'-(2-bromo-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N'-methyl-N'-(2-bromo-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(3-trifluoromethylphenyl)-N,N'-dimethyl-N'-(2-bromo-5-trifluoromethyl
 thiophenyl)guanidine;
 N-(1-naphthyl)-N'-(2-chloro-5-methylthiophenyl)guanidine;
 N-(1-naphthyl)-N'-(2-iodo-5-methylthiophenyl)guanidine; or
 N-(1-naphthyl)-N'-(2-bromo-5-methylthiophenyl)guanidine;
 and pharmaceutically acceptable salts of said compounds.


9. A compound of the following Formula II:



wherein R, R¹ and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R³, R⁴, and each R⁵ substituent are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; n is an integer of from 0-3; or a pharmaceutically acceptable salt thereof.

10. A compound of claim 9 of the following Formula IIa:




wherein R and R² are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted

or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R^3 , R^4 , each R^5 , $R^{3'}$, $R^{4'}$, and each $R^{5'}$ are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; m and n are each independently an integer of from 0 to 3; or a pharmaceutically acceptable salt thereof.

11. A compound of claim 9 of the following Formula IIb:




wherein R, R^1 and R^2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted

aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

R^3 and R^4 are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; or a pharmaceutically acceptable salt thereof.

12. A compound of claim 9 of the following Formula IIc:



wherein R and R^2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaromatic

or heteroalicyclic group having 1 to 3 rings, 3 to 8 ring members in each ring and 1 to 3 hetero atoms;

$R^{3'}$, $R^{4'}$, $R^{3''}$, and each $R^{5'}$ are each independently halogen, hydroxyl, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted carbocyclic aryl, or substituted or unsubstituted aralkyl; n is an integer of from 0 to 3; or a pharmaceutically acceptable salt thereof.

13. A compound of claim 9 that is N-(3-methylsulfonylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfonylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfonylphenyl)-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfinylphenyl)-N-methyl-N'-(2,5-dibromophenyl)guanidine;
N-(3-methylsulfinylphenyl)-N'-methyl-N'-(2,5-dibromophenyl)guanidine;
or N-(3-methylsulfinylphenyl)-N'-(2,5-dibromophenyl)guanidine; and
pharmaceutically acceptable salts thereof.

14. A method of treating a disease of the nervous system in which the pathophysiology of the disorder involves excessive excitation of nerve cells by agonists of NMDA receptors, comprising administering to a mammal exhibiting symptoms of the disease or that exhibits symptoms of the disease or susceptible to the disease an effective amount of a compound of claim 1.

15. The method of claim 14 wherein said disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome or Korsakoff's disease, or wherein the mammal is a human suffering from epilepsy.

16. A method of inhibiting NMDA receptor-ion channel related neurotoxicity in a mammal exhibiting such neurotoxicity or susceptible thereto comprising administering to the mammal an effective amount of a compound of claim 1.

17. The method of claim 16 wherein said neurotoxicity is caused by excessive release of endogenous glutamate following the occurrence of hypoxia, hypoglycemia, brain or spinal chord ischemia, or brain or spinal chord trauma.

18. A method of treating nerve cell death comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1.

19. A method of treating a disease of the nervous system in which the pathophysiology of the disorder involves excessive excitation of nerve cells by agonists of NMDA receptors, comprising administering to a mammal exhibiting symptoms of the disease or that susceptible to of the disease an effective amount of a compound of claim 9.

20. A method of inhibiting NMDA receptor-ion channel related neurotoxicity in a mammal exhibiting such neurotoxicity or susceptible

thereto comprising administering to the mammal an effective amount of a compound of claim 9.

21. A method of treating nerve cell death comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 9.

22. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 9 and a pharmaceutically acceptable carrier.

24. A compound of claim 1 or claim 9 which is radiolabelled.

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US94/06008
A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 514/150, 311,605,633,634;546/134; 552/8;564/99,229,238,239

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/150, 311,605,633,634;546/134; 552/8;564/99,229,238,239

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ON LINE: CA AND REGISTRY FILES

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	WO,A, 91/12797 (Weber et al) 05 September 1991, see entire document.	<u>1-24</u> 1-24
<u>X</u> Y	US,A, 4,906,779 (Weber et al) 06 March 1990, see entire document.	<u>1-12,14-24</u> 1-24
<u>X</u> Y	The Journal of Neuroscience, vol. 9, no. 10, issued October 1989, B.A. Campbell et al, "Sigma Receptors Regulate Contractions of the Guinea Pig Ileum Longitudinal Muscle Myenteric Plexus Preparation Elicited by Both Electrical Stimulation and Exogenous Serotonin", pages 3380-3391, see figure 1, page 3384.	<u>1-6,9-11-22,23</u> 1-12,22-24
<u>X</u> Y	WO, A, 91/18868 (Keana et al) 12 December 1991, see formula I on page 17, pages 25-28, and the examples	<u>1-12,22-24</u> 1-12,22-24

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

01 SEPTEMBER 1994

Date of mailing of the international search report

23 SEP 1994

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PETER G. O'SULLIVAN

LBJ

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US94/06008

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A, 0,179,642 (Ikeda et al) 30 April 1986, see formulas I and II on page 13 and pages 1-25.	1-12,22,23
X	Pakistan Journal of Scientific and Industrial Research, Vol.30, No. 3, issued March 1987, A. Siddiqui et al, "Some Extensions of the Von Braun (BrCN) Reaction on Organic Bases", pages 163-180, see page 170, bottom right and page 172.	1-7,9-11,22, 23
X	Xenobiotica, vol. 23, no. 2, issued February 1993, B. Clement et al. "In Vitro Oxygenation of N,N'-diphenylguanidines", pages 155-167, see page 156.	1-5,9,10,22, 23
X	Chemical Abstracts, vol. 66, issued 17 April 1967, Kiselev et al., "Organic Insecto-fungicides. CVI. A Synthesis of Some Guanidine Derivatives", see abstract No. 75768, Zh. Org. Khim. vol. 2, No. 12, pages 2186-90.	1-6,9,11, 22,23
<u>X</u> Y	US,A, 5,190,976 (Weber et al) 02 March 1993, see entire document.	<u>1-12,14-24</u> 1-24
<u>X P</u> Y	US,A, 5,298,657 (Durant et al) 29 March 1994, see entire document.	<u>1-12,14-23</u> 1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/06008

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-24 as they embrace group I

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06008

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

A61K 31/18,31/47,31/155,31/655; C07C 247/16, 251/38, 279/18, 311/64; C07D 453/02.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-24, drawn to phenyl guanidine compounds substituted by said phenyl moiety and further N-substituted by at least one group selected from the group consisting of optionally substituted phenyl, naphthyl or quinolyl moieties.

II. Claims 1-24, drawn to phenyl guanidine compounds substituted by said phenyl moiety and not further N-substituted by at least one group selected from the group consisting of optionally substituted phenyl, naphthyl or quinolyl moieties.

Groups I and II lack unity of invention under PCT rules 13.1 and 13.2 in that they lack a single inventive concept. PCT administrative instructions Annex B (f) (i).